**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 83540

**Manuscript Type:** REVIEW

**Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease**

Jayasekera D. Noninvasive biomarkers in pediatric NAFLD

Dulshan Jayasekera, Phillipp Hartmann

**Dulshan Jayasekera,** Department of Internal Medicine and Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, United States

**Phillipp Hartmann,** Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of California San Diego, La Jolla, CA 92093, United States

**Author contributions:** Jayasekera D was responsible for writing the manuscript, Hartmann P edited the manuscript.

**Supported by** National Institutes of Health (NIH), No. K12 HD85036; University of California San Diego Altman Clinical and Translational Research Institute (ACTRI)/NIH, No. KL2TR001444; Pinnacle Research Award in Liver Diseases from the American Association for the Study of Liver Diseases Foundation, No. #PNC22-159963; and the Pilot/Feasibility Grant of the San Diego Digestive Diseases Research Center (SDDRC), No. P30 DK120515 (to P.H.).

**Corresponding author: Phillipp Hartmann, MD, Assistant Professor,** Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, United States. phhartmann@health.ucsd.edu

**Received:** January 29, 2023

**Revised:** March 14, 2023

**Accepted:** April 10, 2023

**Published online:**

**Abstract**

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide among children and adolescents. It encompasses a spectrum of disease, from its mildest form of isolated steatosis, to nonalcoholic steatohepatitis (NASH) to liver fibrosis and cirrhosis, or end-stage liver disease. The early diagnosis of pediatric NAFLD is crucial in preventing disease progression and in improving outcomes. Currently, liver biopsy is the gold standard for diagnosing NAFLD. However, given its invasive nature, there has been significant interest in developing noninvasive methods that can be used as accurate alternatives. Here, we review noninvasive biomarkers in pediatric NAFLD, focusing primarily on the diagnostic accuracy of various biomarkers as measured by their area under the receiver operating characteristic, sensitivity, and specificity. We examine two major approaches to noninvasive biomarkers in children with NAFLD. First, the biological approach that quantifies serological biomarkers. This includes the study of individual circulating molecules as biomarkers as well as the use of composite algorithms derived from combinations of biomarkers. The second is a more physical approach that examines data measured through imaging techniques as noninvasive biomarkers for pediatric NAFLD. Each of these approaches was applied to children with NAFLD, NASH, and NAFLD with fibrosis. Finally, we suggest possible areas for future research based on current gaps in knowledge.

**Key Words:** Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Steatosis; Fibrosis; Serological; Imaging

Jayasekera D, Hartmann P. Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease. *World J Hepatol* 2023; In press

**Core Tip:** Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in children and adolescents worldwide. Early diagnosis is essential and currently, liver biopsy is the gold standard for diagnosis and staging. However, noninvasive serological biomarkers, composite scores, and imaging biomarkers are being extensively studied for the diagnosis of NAFLD, nonalcoholic steatohepatitis (NASH), and liver fibrosis in children. This work reviews recent research on noninvasive biomarkers in pediatric NAFLD, identifies circulating biomarkers and imaging techniques that show the most promise, and suggests topics for future research.

**INTRODUCTION**

Pediatric nonalcoholic fatty liver disease (NAFLD) is a spectrum of disease that ranges from isolated steatosis, or nonalcoholic fatty liver (NAFL), to its more severe form nonalcoholic steatohepatitis (NASH) (characterized by ≥ 5% hepatic fat infiltration with inflammation and/or hepatocellular ballooning), to fibrosis and even cirrhosis, or end-stage liver disease. It is the most common cause of chronic liver disease in children[1] and has an estimated global prevalence of 5%–10%[2]. In the United States, NAFLD was found to have a prevalence of 9.6% in children[3]. This percentage increases markedly in pediatric patients with other metabolic conditions including overweight, obesity, type 2 diabetes mellitus and/or dyslipidemia, with a prevalence of up to 50%-80%[4,5].

The early identification and management of pediatric NAFLD is crucial in the prevention of disease progression. Alanine aminotransferase (ALT) levels (with upper limit of normal 26 U/L for boys and 22 U/L for girls) are typically used to screen for NAFLD in patients with risk factors (including overweight/obesity, prediabetes/diabetes, features of metabolic syndrome, positive family history of NAFLD) starting at 9-11 years of age[6]. One study found that using an ALT threshold of twice the upper limit of normal (≥ 50 U/L for boys and ≥ 44 U/L for girls) had a sensitivity of 88% and specificity of 26% for the diagnosis of NAFLD in overweight and obese children[7]. In adults, a two-step approach is often used for screening before considering a liver biopsy. This typically involves using a predictive scoring algorithm (*e.g.* Fibrosis-4 (FIB-4) index), which – if elevated – is followed by subsequent imaging (*e.g.* elastography) to screen for NASH or fibrosis[8,9].

Currently, liver biopsy is considered the most accurate method for diagnosing pediatric NAFLD[6]. The Pathology Committee of the NASH Clinical Research Network (CRN) has developed and validated a scoring system that is widely used to assess the severity of NAFLD. This system includes 14 histological features, four of which are evaluated semi-quantitatively: steatosis (0-3), lobular inflammation (0-3), hepatocellular ballooning (0-2) and fibrosis (0-4). The former 3 features are components of the NAFLD activity score (NAS). A NAS of 5 or higher is indicative of NASH, while scores below 3 suggest simple steatosis, or NAFL[10]. Despite its accuracy, given the invasive nature of liver biopsy, associated sampling error, and high cost, there is a significant need for noninvasive techniques to diagnose pediatric NAFLD, NASH, and fibrosis.

NASH is a more advanced and active form of NAFLD and is characterized by the presence of lobular inflammation and hepatocellular ballooning[11]. Individuals with NASH are at an increased risk of liver fibrosis, with progressive scarring that can lead to cirrhosis. Adult studies have demonstrated that liver fibrosis is the most important histologic feature in determining transplant-free survival in adults with NAFLD[12].

This review summarizes the recent research on noninvasive serological biomarkers (serology-based noninvasive tests, NITs), composite scoring algorithms, and imaging biomarkers (imaging-based NITs) used in the diagnosis of pediatric NAFLD, NASH, and NAFLD with fibrosis.

**Serological Biomarkers / Serology-Based Noninvasive Tests**

***NAFLD***

**Interleukins:** Several studies have explored interleukins as potential noninvasive biomarkers for the diagnosis of NAFLD in children. Interleukin-1β (IL-1β) and IL-6 are secreted by various tissue types, but most abundantly by adipose tissue[13] (Table 1). IL-1β has been implicated in hepatocyte injury and the worsening of NASH[14] while IL-6 is involved in insulin signaling, the synthesis of acute phase proteins, and in regulating chronic inflammation[15]. IL-17 is produced primarily by T helper 17 (Th17) cells[16] and functions by linking T cell activation to neutrophil mobilization and activation. IL-17 has been shown to promote the progression of NASH and fibrosis in animal models[17]. A recent study found that levels of IL-1β, IL-6, and IL-17 were significantly elevated in obese children with NAFLD diagnosed through ultrasound compared to obese controls without NAFLD. These three biomarkers also had excellent diagnostic ability in distinguishing children with obesity and NAFLD from children with obesity without NAFLD. IL-1β had an area under the receiver operating characteristic (AUROC) of 0.94 (cutoff 11.74 pg/mL, sensitivity 84.6%, specificity 85.2%), IL-6 had an AUROC of 0.94 (cutoff 8.10 pg/mL, sensitivity 91.2%, specificity 80.1%), and IL-17 had an AUROC of 0.97 (cutoff 40.03 pg/mL, sensitivity 89.0%, specificity 93.8%)[18] (Table 2).

Flisiak-Jackiewicz *et al*[19] also evaluated IL-18 as a biomarker of liver steatosis in a cohort of 72 obese children with NAFLD diagnosed through magnetic spectroscopy (MRS). IL-18 is a proinflammatory cytokine associated with metabolic syndrome and hepatocyte injury. It is secreted primarily by macrophages, but also by endothelial cells, vascular smooth muscle cells, Kupffer cells, and adipocytes[20,21]. IL-18 was found to be significantly elevated in obese children with NAFLD compared to controls and had an AUROC of 0.68 and a positive predictive value (PPV) of 90% in differentiating between children with or without fatty liver in MRS[19] (cutoff 326.8 pg/mL, sensitivity 60%, specificity 75%). These findings suggest that Interleukins may be promising serology-based NITs in identifying the presence of NAFLD in children with comorbid obesity.

**Adiponectin:** Adiponectin is an adipokine with anti-inflammatory and insulin-sensitizing properties. In the liver, adiponectin triggers the peroxisome proliferator–activated receptor-α (PPAR-α) signaling pathway, leading to increased free fatty acid oxidation and reduced gluconeogenesis, giving it antisteatotic properties[22]. Studies in adults show that patients with NAFLD have lower levels of adiponectin compared to healthy controls, and that these levels are inversely associated with the degree of hepatic steatosis[23]. Multiple studies have found this correlation to be true in children with NAFLD as well. Boyraz *et al*[24] assessed adiponectin levels in 148 obese children, 63 of whom had liver steatosis diagnosed through ultrasound. The study found lower serum adiponectin levels in obese children with liver steatosis compared to obese controls. Adiponectin was able to differentiate children with advanced liver steatosis from those with mild-moderate steatosis with an AUROC of 0.81 (cutoff 2.56 µg/mL, sensitivity 84.21%, specificity 63.64%). In addition, adiponectin was able to differentiate between the presence and absence of NAFLD in obese children with an AUROC of 0.95 (cutoff 3.2 µg/mL, sensitivity 100%, specificity 83.53%). Similarly, in a study of 101 obese children with biopsy-proven NAFLD, Mohamed *et al*[25] showed that adiponectin was able to discriminate between NAFLD patients and healthy controls with an AUROC of 0.92 (cutoff value 2.4 µg/mL, sensitivity 74.26%, specificity 96.49%). These studies suggest that adiponectin may be utilized in identifying NAFLD in children with and without obesity.

**Soluble adiponectin receptor 2:** While adiponectin receptor 2 (Adipo R2) has been studied in children with NAFLD, there are currently no studies evaluating its diagnostic ability in children with NAFLD. Adipo R2 is abundantly expressed in the liver and skeletal muscle and upon binding adiponectin, mediates fatty acid oxidation and glucose metabolism[26,27]. Aksoy *et al*[28] found in a cross-sectional study of 51 obese/overweight children diagnosed with NAFLD through ultrasound that Adipo R2 levels were higher in obese children with NAFLD as opposed to obese controls. While adiponectin levels were similar in patients with and without NAFLD, this entire cohort of children had adiponectin levels below normal. The authors posit that this lower adiponectin level may have driven a compensatory increase in Adipo R2 expression. Studies have established that decreased hepatic Adipo R2 expression can lead to adiponectin resistance, which can subsequently contribute to NAFLD progression given adiponectin’s antisteatotic properties. This is the basis behind the study of adiponectin receptor-sensitizing medications, such as thiazolidinediones, in patients with NASH[29]. Further research is needed to validate Adipo R2 as a clinically feasible diagnostic marker of pediatric NAFLD.

**Fibroblast growth factor 21:** Fibroblast growth factor 21 (FGF21) is a cytokine secreted primarily by hepatocytes, and to a lesser extent by pancreatic, testicular, duodenal, and adipose tissue[30,31]. Liver FGF21 regulates lipid metabolism by promoting lipolysis and reduces hepatic lipid accumulation in an insulin-dependent fashion. Multiple adult studies have found a positive correlation between hepatic steatosis and serum FGF21 levels[32,33]. However, studies in children have been less conclusive. One study found no correlation between FGF21 levels and NAFLD[34], one found greater FGF21 levels in obese children with NAFLD[35], and one showed lower FGF21 levels in children with NAFLD[36]. In a study by Alisi *et al*[36] of 84 children with biopsy-proven NAFLD (38% with NASH, 70% with > F0 fibrosis), median levels of FGF21 were significantly lower in NAFLD patients compared to controls and serum FGF21 levels were inversely associated with the probability of NASH and fibrosis. A 2016 study in mice reported similar findings, noting that FGF21 knockout mice were more prone to developing NASH[37]. A 2019 study in 203 children with steatosis diagnosed through ultrasound found that FGF21 had an AUROC of 0.78 (cutoff 106.10 pg/mL, sensitivity 86.5%, specificity 60%) for the prediction of high-grade liver steatosis in the obese and overweight subjects[38]. However, this AUROC increased when combined with other biomarkers. Composite algorithms are discussed below in further detail (see “NASH scores” and “Fibrosis scores”).

**Resistin and retinol binding protein 4:** Boyraz *et al*[24] also explored resistin and resistin and Retinol Binding Protein 4 (RBP4) as serology-based NITs for pediatric NAFLD. Resistin is a proinflammatory adipokine mainly produced by adipose tissue, inflammatory cells, and hepatic stellate cells[39]. RBP4 is a member of the lipocalin family and is primarily expressed in the liver and adipose tissue[40]; it acts as a carrier of retinol in circulation[41]. Studies have demonstrated that RBP4 and resistin levels are higher in adults with NAFLD compared to controls[39,42]. In differentiating children with advanced steatosis from those with mild-moderate steatosis, resistin had an AUROC of 0.66 (specificity 92.5%) and RBP4 had an AUROC of 0.78 (sensitivity 84.2%). In differentiating children with obesity and NAFLD from controls, resistin and RBP4 had an AUROC of 0.88 (sensitivity 100%) and 0.97 (sensitivity 100%), respectively[24]. Further studies in larger cohorts are required to validate the results of this study and establish resistin and RBP4 as clinically feasible biomarkers for children with NAFLD.

**Chemerin:** Chemerin is an adipokine that enhances insulin-stimulated glucose uptake and insulin sensitivity of adipose tissue[43]. It is highly expressed in the liver and adipose tissue, however, its role in NAFLD is unclear[44] and its functional receptor is only expressed on adipocytes and inflammatory cells[45]. A prospective case-control study of 101 children with biopsy-proven NAFLD found a significantly higher serum chemerin concentration in obese children with NAFLD compared to non-obese controls. In differentiating obese children with NAFLD from controls, chemerin had an AUROC of 0.78 (cutoff value 186.7 ng/mL, sensitivity 56.44%, specificity 87.72%)[25]. Kłusek-Oksiuta *et al*[46] also investigated chemerin and found it was able to differentiate children with fatty liver diagnosed through MRS from those without with an AUROC of 0.70 with an optimal cutoff of 190 ng/mL (sensitivity 75%, specificity 58%). While chemerin shows promise as a noninvasive biomarker, it is not a liver-specific adipokine and therefore, its specificity for NAFLD needs to be further investigated.

**Visfatin:** Visfatin is an adipokine produced by hepatocytes and visceral adipose tissue with a role in glucose and lipid metabolism[44,47,48]. While Genc *et al*[49] suggested that visfatin may play a protective role against liver injury in NAFLD, they found no significant difference in visfatin levels between adults with NAFLD and healthy controls. An Iranian study found that children with obesity had higher serum visfatin levels compared to controls, especially when obesity was comorbid with metabolic syndrome or insulin resistance[50]. In a study of 80 children with obesity (31 of whom had NAFLD as diagnosed *via* ultrasound), serum visfatin levels were higher in children with dyslipidemia, NAFLD, elevated ALT, fibrosis stage 2–3, and steatosis stage 2–3. A visfatin cutoff of 18 ng/mL was reported to significantly detect the presence of NAFLD with high sensitivity (83.9%) and specificity (81.4%), making it a promising biomarker for monitoring NAFLD in children with obesity[47].

***NASH***

NASH is characterized histologically by steatosis, inflammation, and hepatocyte ballooning. Ideal serology-based NITs for NASH would need to highly correlate with these histologic components. This section describes the serological biomarkers that have been investigated thus far in children with NASH (Table 3).

**ALT:** ALT, synthesized primarily within the cytosol of hepatocytes, is still commonly used in both the clinical setting and in clinical trials as an indicator of liver injury and inflammation. This is largely because ALT is widely available, relatively inexpensive, and requires only a small blood sample[51]. Current clinical practice guidelines note that ALT is the best screening test for children with NAFLD and that children older than 10 years with a BMI ≥ 85th percentile should be screened using ALT for NAFLD. In addition, the guidelines state that an ALT > 80 U/L or a persistently elevated ALT greater than twice the upper limit of normal should prompt an evaluation of NAFLD or other causes of chronic hepatitis[6]. However, Manco *et al*[52] demonstrated that children with NAFLD may present with normal ALT levels and Molleston *et al*[53] cautioned that ALT levels may underestimate liver injury in children with NAFLD. In their study of children with biopsy-proven NAFLD, children with normal and mildly elevated ALT showed significant histologic abnormalities including marked steatosis (50% and 24% in patients with mildly elevated and normal ALT, respectively) and advanced fibrosis (stage 3–4 in none of the patients with normal ALT, 9% in patients with mildly elevated ALT, 15% in those with elevated ALT). In addition, ALT did not significantly correlate with hepatocyte ballooning, inflammation, or NAS ≥ 4. This raises concerns about the use of ALT in screening children with NAFLD. Interestingly, a recent study by Arsik *et al*[54] evaluated mean ALT over 96 wk as a biomarker for monitoring change in liver histology in children with biopsy-proven NAFLD. Mean ALT was found to be a better predictor of NASH (AUROC 81.84, sensitivity 80.52%, specificity 82.99%) and NASH + fibrosis (AUROC 77.78, sensitivity 71.76%, specificity 80.81%) compared to change in NAS which had a lower AUROC of 0.63. These findings suggest that ALT may be better utilized as a tool for monitoring histologic change in children with NASH and fibrosis longitudinally rather than as a screening tool.

**Angiopoeitin-2:** Angiopoeitin-2 (Ang-2) is a potent regulator of vascular development and maturation and is synthesized in the liver, kidney, and endothelial cells. Within the liver, it is produced by liver sinusoidal endothelial cells which, when injured, may promote the progression of simple steatosis to NASH[55]. Studies in adults show elevated Ang-2 levels in patients with histological NASH compared to those with isolated steatosis and that Ang-2 levels are associated with steatosis, lobular inflammation, and ballooning, but not with fibrosis[56]. This finding was reproduced by Manco *et al*[57] who investigated levels of Ang-2 and cytokeratin-18 (CK18), an apoptotic marker, in 76 children with biopsy-proven NAFLD. Ang-2 was elevated in children with NAFLD and NASH compared to controls and was able to predict NASH with an AUROC of 0.911 (cutoff 135.4 ng/mL, sensitivity 85.7%, specificity 85.3%, PPV 83%, negative predictive value (NPV) 87.5%). Ang-2 had a poor predictive ability for differentiating fibrosis from non-fibrosis (AUROC 0.475). Ang-2 appears to be useful in predicting NASH, however, further research is required to increase the generalizability of the results published by Manco *et al*[57].

**CK18:** CK18 is a cytoskeletal protein expressed by cells of epithelial origin, including hepatocytes. It is released into the bloodstream during hepatocyte apoptosis as either the whole protein (CK18 M65), which is a measure of total cell death, or the caspase-3-cleaved fragment (CK18 M30), a measure of apoptotic death[58,59]. Several studies have evaluated the use of CK18 in adults with NAFLD in predicting NASH with AUROCs ranging from 0.71 to 0.93[29,60-64]. A meta-analysis of multiple cross-sectional studies showed that CK18 had a pooled AUROC of 0.82 (median sensitivity 78%, specificity 87%) in predicting NASH in adults with NAFLD[29]. A large multicenter study by Feldstein *et al*[64] in 139 adults with biopsy-proven NAFLD found CK18 fragments to have an AUROC of 0.83 (cutoff 279 U/L, sensitivity 71% and specificity 85%) in differentiating NASH from borderline/not NASH, further establishing CK18 as a promising biomarker for adult NASH.

Vos *et al*[65] was the first to study CK18 in a pediatric population in a cross-sectional study of 62 children (20 children with obesity and steatosis as diagnosed through ultrasound/CT/elevated ALT > 40 U/L; 6 of 20 had biopsy-proven NASH). CK18 levels were significantly elevated in children with suspected NAFLD compared to obese/normal weight controls and in a multiple regression analysis, had a prediction accuracy of 84.1% for NAFLD. Feldstein *et al*[66] studied CK18 in 201 children with biopsy-proven NAFLD (NASH (*n* = 140), no-NASH (*n* = 41) and found significantly higher CK18 Levels in children with NASH compared to those with isolated steatosis. The risk of having NASH on liver biopsy increased with increasing CK18 levels and CK18 had excellent accuracy in predicting the presence of NASH on liver biopsy with an AUROC of 0.933 (cutoff of 233 U/L had sensitivity 85% and specificity 86.9%, PPV 93.7%, NPV 71.6%). This AUROC was significantly higher than those of ALT (AUROC 0.635), AST (AUROC 0.651) or GGT (AUROC 0.672) alone. A study of 45 children with biopsy-proven NAFLD in 2010 found the median value of CK18 M30 was significantly higher in children with NAFLD compared to healthy controls. CK18 M30 had an AUROC of 0.85 in predicting NASH/borderline NASH from simple steatosis in patients with NAFLD (cutoff 207 IU/L, sensitivity 84%, specificity of 88%, PPV 90%, NPV 80%)[67].

In a cross-sectional study of 117 children with biopsy-proven NAFLD, greater decreases in serum CK18 levels were observed in children with histologic improvements compared to those without improvement at 1 and 2 years from baseline. However, change in ALT was found to be a better indicator of NASH resolution (AUROC 0.84) compared to CK18, which had an AUROC of 0.69 (*P* = 0.005). Neither change in ALT, change in CK18, or change in CK18 + ALT had significantly different AUROCs for discriminating a ≥ 1 point decrease in steatosis, lobular inflammation, hepatocyte ballooning, or fibrosis stage[68]. Further research is required to determine the usefulness of CK18 Levels in tracking the progression of NASH over time. CK18 as a predictor of pediatric liver fibrosis is discussed in the section on diagnosing liver fibrosis below.

**Cathepsin D:** Cathepsin D (CatD) is a lysosomal protease that is ubiquitously distributed in high concentrations in the liver[69]. Thus far, it has only been evaluated as a biomarker for children in one study. Walenbergh *et al*[70] evaluated the predictive ability of CatD for hepatic inflammation in 96 children with biopsy-proven NAFLD (NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19). The study found that plasma CatD was significantly lower in children with liver inflammation compared to those with steatosis, and had a negative correlation with increasing liver inflammation, steatosis, hepatocellular ballooning, and NAS. CatD had a high diagnostic accuracy in differentiating between NASH and steatosis with an AUROC of 0.94 and reached an AUROC of 0.998 when combined with CK18. A cutoff of < 18445 pg/mL had a sensitivity of 100% and specificity of 89.5% (PPV 92.9%, NPV 100%). CatD as a solo biomarker was also superior in differentiating NASH from steatosis in children with NAFLD compared to ALT (AUROC 0.59) and CK18 (AUROC 0.72). Additionally, CatD was able to accurately distinguish borderline NASH from definite NASH (AUROC 0.85), steatosis + borderline NASH from definite NASH (AUROC 0.88) and steatosis from borderline NASH + definite NASH (AUROC 0.81), better than ALT or CK18 could on their own. The combination of CatD with CK18 improved the discriminatory ability in each of the aforementioned categories[70]. Interestingly, a second study conducted by Walenbergh *et al*[71] in 2016 found that in 248 adults with biopsy-proven NAFLD, patients with NASH had increased levels of CatD compared to healthy controls. Following surgical intervention there was a reduction of plasma CatD compared to baseline. This suggests the presence of distinct pathophysiology between childhood and adulthood NASH.

**Cytokines:** Cytokines have also been studied as serology-based NITs for pediatric NASH. A cross-sectional NASH CRN study found that in 235 children with biopsy-proven NAFLD, certain cytokines were significantly associated with different histologic features of NASH. Children with definite NASH and lobular inflammation were found to have significantly higher levels of total (tPAI1) and activated tissue plasminogen activator 1 (aPAI1). In addition, PAI1 was able to significantly discriminate between borderline/definite NASH, definite NASH, lobular inflammation, and hepatocyte ballooning. IL-8 and soluble IL-2 receptor alpha (sIL-2Rα) were associated with fibrosis severity and with lobular and portal inflammation, respectively[72]. These findings suggest that these novel cytokines may be a useful tool in the diagnosis and management of NASH in children. However, more research is needed to validate these results and explore the utility of these biomarkers in clinical practice.

***Fibrosis***

Currently, liver biopsy remains the gold standard for diagnosing fibrosis in children with NAFLD. However, there is a growing need for noninvasive, more cost-effective diagnostic methods. There have been many advances in recent years in developing noninvasive techniques for diagnosing liver fibrosis, including serological biomarkers, scores based on basic laboratory tests, and imaging modalities. This section discusses the serological biomarkers used in the diagnosis of liver fibrosis in pediatric NAFLD (Table 4). It is important to note that to date, two milestone studies have identified liver fibrosis as the strongest prognostic factor in predicting long-term outcomes in patients with NAFLD[12,73].

Fibrosis is most commonly scored based on the Metavir score, which includes 5 histologic categories: F0 (no fibrosis), F1 (portal fibrosis with no septae), F1 (portal fibrosis with few septae), F3 (numerous septae without cirrhosis), and F4 (cirrhosis). Any fibrosis refers to F1–F4, F2–F4 are considered significant fibrosis, and F3–F4 are considered advanced fibrosis[74].

**Hyaluronic acid:** Hyaluronic acid (HA) is a glycosaminoglycan polymer present in epithelial and connective tissue and constitutes a major component of the extracellular matrix (ECM). HA is abundant in the ECM of the liver. Within the liver, HA is primarily produced by activated hepatic stellate cells and degraded by sinusoidal endothelial cells[75]. In adults with NAFLD, HA has emerged as a good predictor of liver fibrosis[76-78]. In 2010, Nobili *et al*[79] were the first to evaluate HA as a predictive biomarker in children with NAFLD. This study included 100 children with biopsy-proven NAFLD, 65% of whom had ≥ stage 1 Liver fibrosis. The study found that serum HA was a good predictor of the degree of fibrosis in children with NAFLD, with HA ≥ 1200 ng/mL making the absence of fibrosis (F0) unlikely and HA ≥ 2100 ng/mL making significant fibrosis (≥ F2) highly likely. Serum HA as a diagnostic tool for liver fibrosis had an AUROC of 0.88 for any degree of fibrosis (F1-F4 *vs* F0) when using a cutoff of ≥ 1200 ng/mL (PPV 90%, NPV 53%) and an AUROC of 0.95 for significant fibrosis (≥ F2+ *vs* F0-F1) using a cutoff of 2100 ng/mL (PPV 40%, NPV 91%).

In 2011, Lebensztejn *et al*[80] found that HA was significantly higher in children with biopsy-proven NAFLD who had fibrosis compared to healthy controls. With a cutoff value at 19.1 ng/mL, HA had an AUROC of 0.672 (sensitivity 84%, specificity 55%, PPV 52%, NPV 86%) in differentiating children with NAFLD and fibrosis (F1–F3) from those without fibrosis (F0). When combined with CK18, the AUROC increased to 0.73 (sensitivity 74%, specificity 79%, PPV 56%, NPV 63%). Notably, 37% (19 of 52) of this cohort of children had fibrosis (F1–F3). Interestingly, the 2010 study by Fitzpatrick *et al*[67] that evaluated CK18 M30 and leptin as biomarkers in 45 children with biopsy-proven NAFLD did not find HA to be a reliable marker of NASH or fibrosis, despite 51.1% of the cohort having ≥ F2 (significant fibrosis).

**N-terminal type III collagen propeptide:** Fibrosis is a dynamic process that results from the imbalanced production and degradation of ECM proteins, leading to the continuous release of ECM-related proteins into the serum. N-terminal type III collagen propeptide (PRO-C3), a neo-epitope pro-peptide of type III collagen formation, has been studied as an independent predictor of the degree of fibrosis in adults with NAFLD[81]. One such adult study created a PRO-C3 based fibrosis algorithm, named ADAPT (age, presence of diabetes, PRO-C3, and platelet count), that had an AUROC of 0.86–0.87 in identifying patients with NAFLD and advanced fibrosis and superior to other fibrosis algorithms such as the Fibrosis-4 (FIB-4) score, NAFLD Fibrosis Score (NFS), and AST to Platelet Ratio index (APRI)[82]. Only one group has studied PRO-C3 as a serological marker of fibrosis in pediatric NAFLD. Cohen *et al*[83], in a study of 88 children with biopsy-proven NAFLD, found that PRO-C3 levels were similar between children with NAFLD and healthy controls, but significantly lower in children ≥ 15 years compared to children ≤ 10 years old. Amongst children with NAFLD, PRO-C3 levels were higher in children with advanced fibrosis (Ishak score ≥ 3) compared to children with no/mild fibrosis (Ishak score ≤ 2). However, these associations were not significant after adjusting for bone remodeling biomarkers, suggesting that PRO-C3 may not be a reliable biomarker for liver fibrosis until late adolescence, as it is influenced by age and pubertal growth.

**CK18:** While CK18 has been extensively studied as a marker of pediatric NASH, there is limited data on it as a marker for pediatric liver fibrosis. Lebensztejn *et al*[80] found that CK18 had an AUROC of 0.666 (cutoff 210 U/L, sensitivity 79%, specificity 60%, PPV 56%, NPV 82%) in differentiating children with fibrosis from those without fibrosis. When combined with HA, this AUROC increased to 0.73. In 2010, Fitzpatrick *et al*[67] found that CK18 M30 fragments were significantly higher in children with significant or severe fibrosis (≥ F2) compared to children with no/minimal fibrosis (< F2). CK18 M30 had an AUROC of 0.66 in predicting significant/severe fibrosis (≥ F2) (cutoff 200 IU/L, sensitivity 83%, specificity 40%). A more recent study by Mandelia *et al*[84] of 201 children with biopsy-proven NAFLD (68% of cohort with F1–F3 fibrosis) found CK18 levels to be significantly higher in children with F1–F3 compared to F0. Their study had an AUROC of 0.75 in predicting any fibrosis (F1–F3), AUROC 0.67 in predicting significant fibrosis (F2–F3) and AUROC 0.77 in predicting advanced fibrosis (F3). Mandelia *et al*[84] also generated a prediction model for fibrosis F1–F3 that combined CK18 with waist circumference percentile which reached an AUROC of 0.842 of differentiating any fibrosis (F1–F3) from no fibrosis (F0). Using this model, they propose that patients with a score of < 35 likely have no fibrosis (specificity 38%, sensitivity 97%, PPV 76%, NPV 86%) and patients with a score ≥ 82 likely have fibrosis (sensitivity 88%, specificity 59%, PPV 91%, NPV 51%).

**ECM associated noninvasive tests:** Several ECM biomarkers have been studied in adults with NAFLD as biomarkers of fibrosis, including laminin, chitinase-3-like protein 1 (YKL-40), amino-terminal propeptide of type III procollagen (PIIINP), and tissue inhibitor of metalloproteinases 1 (TIMP1). YKL-40 is a glycoprotein with an unknown biological purpose, but it is known to promote growth in fibroblasts, chondrocytes, and synovial cells. During fibrogenesis, YKL-40 is released from the hepatic stellate cells[85]. Lebensztejn *et al*[80] are the only group to study laminin and YKL-40 in children with NAFLD and found that while they were significantly higher in NAFLD patients with fibrosis compared to healthy controls, neither correlated with fibrosis stage or were useful in predicting fibrosis in children with biopsy-proven NAFLD.

**Leptin:** Leptin is an adipocyte-derived hormone that plays a major role in the regulation of appetite and body fat mass and controls energy balance in the hypo- and normoleptinemic states[86,87]. Within the liver, leptin is thought to increase hepatic steatosis, steatohepatitis, and fibrosis[88]. Leptin has been established as an essential mediator of fibrosis in response to chronic liver injury. A 2002 study demonstrated that Leptin-deficient mice failed to develop fibrosis during steatohepatitis or in response to chronic toxic liver injury[89]. Leptin exerts its profibrotic effects by activating Kupffer cells and macrophages and stimulating endothelial cells to secrete transforming growth factor-β (TGF-β)[90]. In addition, leptin directly targets hepatic stellate cells through the stimulation of TIMP1 production[91]. Leptin also protects hepatic stellate cells from apoptosis, leading to a cycle that exacerbates its profibrotic effects[92,93]. Studies in adults with NAFLD have found that leptin levels increase in association with increased severity of hepatic steatosis and degree of fibrosis, especially in patients with a high BMI[94].

Studies have also been conducted evaluating the role of leptin in pediatric NAFLD. In a study of 72 children with biopsy-proven NAFLD (36 children each in the training set and validation set), Manco *et al*[95] found that leptin had an AUROC of 0.796-0.833 in predicting a NAS of ≥ 5. In the training set, a leptin cutoff of ≥ 20.4 ng/mL had sensitivity 54%, specificity 76%, PPV 50%, NPV 79%. A risk score that was developed by combining leptin with tumor necrosis factor α (TNF-α) had an AUROC of 0.964–0.985. The risk score showed high accuracy, with a cutoff of ≥ 13.5 having sensitivity 81%, specificity 92%, PPV 82%, NPV 92%. This is currently the only study that has done receiver operating characteristic (ROC) analysis regarding leptin in children with NAFLD. However, other studies have evaluated leptin in pediatric NAFLD with varying results. The most recent study by Brandt *et al*[96] found that in a cross-sectional study of 97 prepubertal children with obesity (34% of whom were diagnosed with hepatic steatosis through ultrasound), circulating leptin levels were negatively correlated with the degree of hepatic steatosis. However, Nobili *et al*[97] found that circulating leptin levels positively correlated with degree of hepatic steatosis, ballooning, and NAS (independently of age, BMI and gender) in the same cohort of 72 biopsy-proven NAFLD children studied by Manco *et al*[97]. Boyraz *et al*[24] similarly found that leptin levels were higher in obese children with steatosis, but that leptin was unable to differentiate obese children with steatosis from obese children without steatosis. A 2010 study by Fitzpatrick *et al*[67] in 45 children with biopsy-proven NAFLD found that leptin was able to accurately predict fibrosis grade but not degree of steatohepatitis. Leptin was able to distinguish.

**PIIINP:** PIIINP is a peptide released during the processing of procollagen. It was first studied in 1984 and found to be normal or slightly elevated in adults with NAFLD[98]. In a cross-sectional case-control study of 55 obese children (50 of whom were diagnosed with NAFLD through ultrasound), a PIIINP cutoff of 8.5 ng/mL yield a sensitivity of 74%, specificity 33% in differentiating cases from controls, suggesting that PIIINP may serve as a marker of hepatic steatosis[99]. A study of 172 adults with biopsy-proven NAFLD demonstrated that in patients with F0–F2 fibrosis, PIIINP had an AUROC of 0.77–0.82 in discriminating between NASH and simple steatosis, and in patients with F0–F3, an AUROC of 0.82–0.84. When considering patients with all levels of fibrosis, PIIINP was successful in distinguishing between those with simple steatosis and those with NASH or advanced fibrosis with an AUROC of 0.85-0.87[100]. Mosca *et al*[101] are the only study to date to evaluate PIIINP in a biopsy-proven cohort of 204 children with NAFLD. This study found that children with NASH had higher plasma PIIINP levels compared to children without NASH, and that PIIINP levels correlated with NAS and its constituent components. The risk of NASH and ≥ F2 progressively increased with increasing PIIINP levels (for every 3.6 ng/mL increase in PIIINP levels, the likelihood of having ≥ F2 increased by approximately 14 fold). PIIINP had an AUROC of 0.737 (sensitivity 62%, specificity 91%, PPV 85%, NPV 75%) in discriminating definite NASH from no/borderline NASH. This is higher than the discriminatory ability of the FIB-4 score or APRI (AUROC 0.6369 and 0.6826, respectively). PIIINP had an AUROC of 0.921 for ≥ F2 and 0.993 for F3. A cutoff of > 8.89 ng/mL had 84% sensitivity, 94% specificity, 95% PPV, 79% NPV for predicting ≥ F2, whereas a cutoff of > 13.2 ng/mL yielded 100% sensitivity, 98% specificity, 70% PPV, 100% NPV for predicting the presence of F3. These values were higher than those of FIB-4 (AUROC 0.7412 for ≥ F2 and AUROC 0.7687 for F3) and APRI (AUROC 0.7659 for ≥ F2 and AUROC 0.8535 for F3).

**Imaging­-Based Biomarkers / Imaging­-Based Noninvasive Tests**

***Ultrasound-based biomarkers***

**Steatosis (primarily controlled attenuation parameter, or CAP):** The ultrasound-based FibroScan® can evaluate the severity of hepatic steatosis and fibrosis. Its best-known function is based on vibration-controlled transient elastography (VCTE) for fibrosis assessment, which works by sending a low-frequency ultrasound shear wave into the liver and measuring the velocity of the wave as it passes through liver tissue. Firmer tissue results in faster wave propagation. This measurement is converted into a liver stiffness measurement (LSM), expressed in kilopascals (kPa), which is able to assess the level of fibrosis in the liver[102]. Moreover, the FibroScan® is also able to assess liver steatosis through a measure called controlled attenuation parameter (CAP), expressed as decibels per meter (dB/m), which measures the amount of attenuation of the ultrasound wave as it passes through liver tissue. Higher values of CAP indicate a greater level of hepatic steatosis[103].

Kwon *et al*[104] evaluated the usefulness of FibroScan® in a Korean cohort of 59 obese children and 47 non-obese controls. The study found that children in the obese group had significantly higher levels of CAP and LSM compared to controls and that LSM had a strong positive correlation with conventional predictive indices for hepatic steatosis and fibrosis, including AST, ALT, and APRI. A recent study by Chaidez *et al*[105] found CAP to have outstanding discriminatory ability in differentiating steatosis grade 1–3 from grade 0 (AUROC 0.98) (Table 5). A CAP cutoff value of ≥ 259 dB/m had a sensitivity of 94%, specificity of 91%, PPV of 97%, and NPV of 91% for the prediction of steatosis grades 1–3.

Yang *et al*[106] evaluated the diagnostic efficacy of LSM in NAFLD and its subtypes, NAFL and NASH, in a cohort of 120 children with obesity. The results showed that LSM had an AUROC of 0.768 (sensitivity 70.5%, specificity 70.7%) for NAFLD, an AUROC of 0.674 (sensitivity 61.4%, specificity 64.5%) for NAFL, and an AUROC of 0.725 (sensitivity 64.7%, specificity 65.0%) for NASH. The study concluded that LSM has diagnostic efficacy for NAFLD and its subtypes in children with obesity with optimal predictive values for NAFLD being LSM > 4.65 kPa, for NAFL being LSM > 4.95 kPa, and for NASH being LSM > 5.15 kPa. It is important to note that LSM is typically used in the evaluation of fibrosis, however, in this study LSM was used for the evaluation of steatosis. This study also evaluated CAP with results showing that CAP had an AUROC of 0.757 (sensitivity 67.20%, specificity 67.20%) for NAFLD, an AUROC of 0.659 (sensitivity 59.10%, specificity 60.50%) for NAFL, and an AUROC of 0.722 (sensitivity 70.60%, specificity 72.80%) for NASH. The study concluded that CAP has diagnostic efficacy for NAFLD and its subtypes in children with obesity with optimal predictive values for NAFLD being CAP > 258.00 dB/m, for NAFL being CAP > 262.50 dB/m and for NASH being CAP > 276.00 dB/m.

***NASH***

Yang *et al*[106] also evaluated the ability of CAP and LSM in predicting NASH in children with obesity. They found that CAP had an AUROC of 0.722 (sensitivity 70.6%, specificity 72.8%) and LSM had an AUROC of 0.725 (sensitivity 64.7%, specificity 65%) in predicting NASH in children with obesity (Table 6). The optimal cutoff points were > 276 dB/m and > 5.15 kPa for CAP and LSM, respectively.

***Fibrosis***

**Transient elastography/VCTE**: Transient elastography (TE) has shown excellent performance in determining the severity of fibrosis in children with NAFLD in two large studies. In a cohort of 52 children with biopsy-proven NASH, Nobili *et al*[107] demonstrated that TE was able to predict any fibrosis (F1–F4) with an AUROC of 0.977 (cutoff of 5.1 kPa yielded sensitivity 97%, specificity 91%, PPV 97%, NPV 91%) (Table 6). It predicted significant fibrosis (F2-F4) with an AUROC of 0.992 and at a cutoff of 7.4 kPa, had sensitivity 100%, specificity 92%, PPV 80%, NPV 100%. TE was also able to predict advanced fibrosis (F3–F4) with an AUROC of 1.000 and at a cutoff of 10.2 kPa, had a sensitivity, specificity, PPV, and NPV all of 100%. Alkhouri *et al*[108] evaluated the ability of TE in predicting clinically significant (≥ F2) fibrosis in children with NAFLD. In their cohort of 67 children with biopsy-proven NAFLD (10 of whom had F2–F3 fibrosis), TE demonstrated an AUROC of 1.00 in predicting ≥ F2 fibrosis. A cutoff of 8.6 kPa yield 100% accuracy in predicting F0–F1 fibrosis, obviating the need for liver biopsy, and a cutoff of ≥ 8.6 kPa had 100% accuracy in predicting F2–F3 fibrosis, highlighting the need for liver biopsy. The ability of LSM to predict fibrosis stage was evaluated in a recent study by Chaidez *et al*[105] by comparing LSM to 4 dichotomized outcomes of the Ishak fibrosis scale: no fibrosis (F0) *vs* any fibrosis (F1-F6), mild fibrosis (F0-F1) *vs* moderate-to-severe fibrosis (F2-F6), mild-to-moderate fibrosis (F0-F2) *vs* severe fibrosis (F3-F6), and mild-to-severe fibrosis (F0-F3) *vs* very severe fibrosis (F4-F6). LSM had the strongest discriminatory ability in comparing mild-to-moderate fibrosis (F0-F2) with severe fibrosis (F3-F6) with an AUROC of 0.7 for the NAFLD group (*n* = 116), 0.77 for the non-NAFLD group (*n* = 90), and 0.73 for all participants (*n* = 206).

**Acoustic radiation force impulse:** Acoustic radiation force impulse (ARFI) is a noninvasive ultrasonography technique that uses short, high-intensity acoustic pulses to generate shear waves in the liver. These waves propagate at a speed proportional to the stiffness of the tissue, thus traveling faster as the degree of fibrosis increases. These waves are measured as shear wave velocity (SWV) and provide information about the mechanical qualities of the liver being measured. A systematic review of 7 studies (723 adult patients with NAFLD) showed that ARFI had a diagnostic accuracy of 90% in detecting significant fibrosis (sensitivity 80%, specificity 85%)[109]. While there have been studies looking at ARFI in children with fibrosis and chronic liver disease, data on the performance of ARFI specifically in children with NAFLD are limited. One pediatric study found that ARFI values correlated strongly with AST/ALT ratios in obese children. In this study of 54 obese children, 90.7% had ARFI < 1.19 m/s (normal), 7.4% had ARFI values between 1.19 and 1.75 m/s, and 1.9% had ARFI > 1.75 m/s[110]. In another study of 148 school children (33.8% with NAFLD), ARFI values were found to correlate positively with hepatic steatosis grades. ARFI detected significant fibrosis (SWV > 1.60 m/s) in 7.5% of children, 6% of whom had a normal or mildly steatotic liver on ultrasound, suggesting that children with normal/mild steatosis on ultrasound may have significant fibrosis[111]. In a study of 39 children with various biopsy-proven liver etiologies, a SWV of 2.0 m/s had a sensitivity of 100% in detecting advanced fibrosis (≥ F3)[112]. A similar study found that in 52 children with chronic liver disease, ARFI was able to discriminate ≥ F1 fibrosis with an AUROC of 0.834 (sensitivity 78.9%, specificity 76.9%), ≤ F2 with an AUROC of 0.818 (sensitivity 87.5%, specificity 75%), and F4 with an AUROC of 0.983 (sensitivity 100%, specificity 96.7%)[113]. Further research is required to investigate ARFI as an imaging-based NIT in the pediatric NAFLD population.

***Magnetic resonance imaging-based biomarkers***

**Steatosis (MRI-proton density fat fraction, or MRI-PDFF):** Magnetic resonance imaging (MRI) is a noninvasive technique that can be used in the evaluation of hepatic steatosis. Magnetic resonance (MR)-based methods are able to measure hepatic fat as a continuous variable and typically measure the signal fat fraction, which is the fraction of the MR signal attributable to hepatic fat. However, this measure can be affected by numerous confounding variables and is scanner dependent. The PDFF removes these confounders and reflects the fraction of the liver proton density attributable to hepatic fat. This is a direct measure of hepatic fat content and is a fundamental property of the hepatic tissue[114,115].

Several studies have shown MRI-PDFF to strongly correlate with histology steatosis grade in adults[116-119]. A 2015 study in children with biopsy-proven NAFLD found that MRI-PDFF was significantly correlated with steatosis grade and that this correlation was influenced by sex and fibrosis stage. The correlation was stronger in girls compared to boys, and weaker in children with more severe fibrosis (F2–F4) compared to mild fibrosis (F0–F1)[120]. In 2018, a multicenter study in children with biopsy-proven NAFLD found that MRI-PDFF had a high diagnostic accuracy in predicting both histologic steatosis grade and change in histologic steatosis grade over time. It found that MRI-PDFF could discriminate between grade 1 steatosis and grade 2–3 steatosis with an AUROC of 0.87 (at a cutoff of 17.5%, it has a sensitivity of 74%, specificity of 90%, PPV of 97%, and NPV of 41%). It could also discriminate grade 1-2 steatosis from grade 3 steatosis with an AUROC of 0.79 (at a cutoff of 23.3%, it yielded the following: sensitivity 60%, specificity 90%, PPV 88%, NPV 65%). MRI-PDFF was able to classify improvement in steatosis grade with an AUROC of 0.76 (sensitivity 31%, specificity 90%, PPV 75%, NPV 60%), and worsening with an AUROC of 0.83 (sensitivity 40%, specificity 90%, PPV 33%, NPV 92%)[121].

A few studies have also investigated MRI-PDFF in discriminating between the presence and absence of steatosis. In 2016, a study of 27 children with biopsy-proven NASH found that a cutoff of 3.5% allowed MRI-PDFF to differentiate between children with NAFLD and healthy controls with a sensitivity of 89% and specificity of 88%[122]. A more recent study including 86 children and adolescents (65 overweight or obese), further investigated the accuracy of MRI in quantifying liver fat against a reference of MRS. MRI-PDFF predicted the presence of steatosis with an AUROC of 0.981 and at a cutoff of 5.4%, yield a sensitivity of 95% and specificity of 91.4%[123].

Recently, Jia *et al*[124] conducted a meta-analysis that showed that MRI-PDFF was accurately able to diagnose stage 1–3 steatosis with a summary sensitivity of 95%, specificity of 92% and hierarchical summary ROC (HSROC) of 0.96. MRI-PDFF was additionally found to be more accurate in assessing steatosis in children compared to TE, which had an HSROC of 0.94 with a sensitivity of 86% and specificity of 88% in differentiating S1–3 from S0. The high diagnostic accuracy and noninvasive nature of MRI-PDFF, therefore, make it a powerful tool in the evaluation of hepatic steatosis in children.

**NASH:** There are currently no MR-based imaging studies evaluating NASH in children. Even in adults, multiparametric MRE has only limited diagnostic accuracy for NASH[125]. However, a meta-analysis by Kim *et al*[126] which included 485 patients, 207 of whom had simple steatosis and 278 of whom had NASH found that MRI was able to detect NASH with an AUROC of 0.89 and had a pooled sensitivity of 87.4% and pooled specificity of 74.3%. Further research is needed to see whether MR is a feasible technique for diagnosing NASH in children.

**Fibrosis (magnetic resonance elastography):** Magnetic resonance elastography (MRE) is an MRI-based, noninvasive tool that can be used to diagnose fibrosis in patients with NAFLD and NASH. It uses propagating mechanical shear waves to determine the mechanical properties of hepatic tissue[127]. These shear waves propagate faster in stiffer tissue and the collected wave data is processed by an inversion algorithm that generates cross-sectional, quantitative depictions of the stiffness of hepatic tissue. Unlike ultrasound-based modalities, which provide localized measurements with limited penetration, MRE is able to provide quantitative maps of large regions of the abdomen at a greater depth, making results independent of abdominal wall fat deposition[128]. Studies have shown that MRE is able to accurately determine liver stiffness and assess fibrosis in adults with liver fibrosis[129,130], with an AUROC of 0.86 in predicting advanced fibrosis[131]. However, MRE has not reflected the high accuracy seen in adults in the pediatric population.

In a case-series of 35 children with 8 different biopsy-proven chronic liver diseases, Xanthakos *et al*[132] found that an MRE cutoff of 2.71 kPa had a sensitivity of 88% and specificity of 85% in discriminating F0–F1 from F2–F4 fibrosis. MRE had an AUROC of 0.92 in this study for detecting significant fibrosis. In a multicenter study of 90 pediatric patients, Schwimmer *et al*[133] evaluated the diagnostic utility of two-dimensional gradient-recalled echo MRE (2D GRE MRE) in conjunction with liver biopsy for fibrosis. The study participants, with a mean age of 13.1 ± 2.4 years and 73% male, underwent MRE within 6 mo of liver biopsy. The study found an AUROC of 0.77–0.79 for detection of any fibrosis (≥ F1) and a cutoff of 3.03–3.05 for detection of advanced fibrosis (≥ F3) with an AUROC of 0.88–0.93, sensitivity of 33.3%−50%, specificity of 91.7–94%, PPV of 28.6–30%, and NPV of 95.2–96.2%. The authors caution that cutoffs validated in adult populations may not be appropriate for interpreting pediatric MRE results. Trout *et al*[134] found that MRE had an AUROC of 0.70 for differentiating Ludwig stage 0–1 from ≥ stage 2 fibrosis (defined as fibrosis with few bridges or septa)[135] in 86 children and young adults with a spectrum of biopsy-proven liver diseases. A cutoff of ≥ 2.27 kPa had sensitivity 68.6% and specificity 74.3% while a cutoff of ≥ 1.67 kPa had sensitivity 35.3%, specificity 91.4%. This study also found an AUROC of 0.90 for discriminating Ludwig stage 0–2 from ≥ Ludwig stage 3 (numerous bridges or septa). A cutoff of 5.41 kPa had a sensitivity of 64.3% and specificity of 93.1%. The study found that MRE was able to better distinguish between stage 0–1 and stage 2–4 fibrosis in patients without steatosis compared to patients with steatosis; suggesting that steatosis was playing a confounding effect in children with NAFLD[134]. A 2019 study in 69 children with biopsy-proven NAFLD found that MRE liver stiffness values (based on 2D GRE or 2D spin-echo echo-planar imaging pulse sequence) did not significantly differentiate ≥ F2 from[136].

**Novel Composite Scores**

While several circulating biomarkers have shown promise in their diagnostic abilities for NAFLD, NASH, and fibrosis, none are currently being used in lieu of liver biopsy in the clinical setting. Multiple studies have demonstrated that novel composite algorithms that combine multiple serological biomarkers can sometimes have higher diagnostic accuracy than their solo components.

**NASH Scores**

Manco *et al*[57] showed that a combination of Ang-2 and CK18 was able to predict NASH with a sensitivity of 71.4%, specificity of 100% (PPV 100%, NPV 80.4%), which was superior to Ang-2 or CK18 alone (Table 7). Similarly, combining CK18 with CatD was able to discriminate steatosis from NASH with an AUROC of 0.998, compared to CK18 (AUROC 0.72) or CatD (AUROC 0.94) alone[70].

A study by Kwon *et al*[137] looked at the use of bone formation biomarkers in children with NAFLD. Procollagen type 1 amino-terminal propeptide (P1NP) is a protein secreted by the ECM that has been implicated in liver disease in adults[138] and in liver fibrogenesis in animal models[139]. P1NP is typically elevated in children and adolescents compared to adults given their increased rate of bone formation. To correct for this, the researchers measured levels of serum osteocalcin, another marker of bone formation, and alkaline phosphatase (ALP), in the study cohort. The study found that the P1NP/osteocalcin ratio alone had a diagnostic capability for evaluating steatohepatitis (early fibrosis) with an AUROC of 0.782 (sensitivity 80.9%, specificity 76.9%). However, the diagnostic capability was higher when the ratio was multiplied by ALT, with an AUROC of 0.939 (sensitivity 83%, specificity 92.3%). Similarly, the P1NP/ALP ratio alone had a diagnostic capability with an AUROC of 0.788 (sensitivity 78.8%, specificity 81.3%), but it also showed better diagnostic capability when multiplied by ALT, with an AUROC of 0.894 (sensitivity 82.6%, specificity 92.9%)[137].

**Fibrosis Scores**

Liver fibrosis has been well-established as the most important determinant for survival in adults with NAFLD[12]. As end-stage liver disease [also known as cirrhosis (F4)] exists at the end of the fibrosis staging scale, higher fibrosis stages are more likely to progress to cirrhosis compared to earlier stages. Multiple scoring systems have been developed to determine the level of fibrosis in adults with NAFLD, including the AST/ALT ratio, APRI, FIB-4, and NFS. Studies in the last decade have shown that these scores may not be accurately used in the pediatric population for predicting fibrosis[140,141]. There have also been scores that have been developed specifically for children, including the pediatric NAFLD fibrosis index (PNFI) and pediatric NAFLD fibrosis score (PNFS). This section will discuss these simple scoring algorithms and novel composite algorithms for the diagnosis of fibrosis in children with NAFLD (Table 8).

***Simple fibrosis scores***

Pediatric studies have evaluated simple serum tests such as ALT, AST/ALT ratio, APRI, NFS, and FIB-4 for their diagnostic performance in detecting fibrosis. These tests have been well-studied in adult populations. One pediatric study reported poor diagnostic performance in detecting any fibrosis (≥ F1) for the AST/ALT ratio (AUROC 0.572), FIB-4 (AUROC 0.547), and NFS (AUROC 0.470). However, all three tests performed better for the detection of significant fibrosis (≥ F2): AST/ALT ratio (AUROC 0.585), FIB-4 (AUROC 0.686), and NFS (AUROC 0.554). APRI had the best performance of the surveyed tests, with an AUROC of 0.800 for the detection of any fibrosis (≥ F1) and 0.628-0.70 for ≥ F3-4 in the pediatric NAFLD population[140].

A recent study by Mosca *et al*[142] also evaluated APRI, FIB-4, NFS, and a score called Hepamet in predicting the degree of fibrosis in 286 children with biopsy-proven NAFLD. The Hepamet fibrosis score (HFS) is based on demographic and laboratory data (including sex, age, +/- diabetes, and serum lab values) and was developed to identify adult patients with NAFLD at risk for advanced fibrosis. HFS was able to discriminate between adults with and without advanced fibrosis with an AUROC 0.85 compared to NFS and FIB-4 with AUROC 0.80 (*P* = 0.0001)[143]. The study by Mosca *et al*[142] found that APRI had an AUROC of 0.61 (PPV 62.77%, NPV 52.01%) in identifying > F1 fibrosis in children with NAFLD compared to Hepamet which had an AUROC of 0.778 (PPV 63.24%, NPV 61.29%). NFS and FIB-4 both had poor accuracy for the diagnosis of fibrosis with both having AUROC 0.54 (PPV 62%, NPV 52%). APRI and Hepamet both had an AUROC of 0.74 in identifying the presence of > F2 fibrosis, higher than those for FIB-4 and NFS (AUROC 0.58–0.60). Interestingly, PNFI had a higher AUROC for identifying both > F1 (AUROC 0.81) and > F2 (AUROC 0.84) compared to these other scores. PNFI was the best noninvasive biomarker in the pediatric age, however, Hepamet showed promise[142].

***FibroScan-aspartate aminotransferase score***

The FibroScan-aspartate aminotransferase (FAST) score is calculated using LSM, CAP, and serum AST and is used to predict liver disease severity in adults with NAFLD. In adults, it has been found to be an efficient way to non-invasively identify patients at risk of progressive NASH for clinical trials or treatments[144]. Chaidez *et al*[105] found that the FAST score had acceptable discriminatory ability for significant liver disease (NAS ≥ 4 and Ishak ≥ 3) with an AUROC of 0.75. At a cutoff of ≥ 0.67, it had a sensitivity 89% and specificity 62%.

***Pediatric NAFLD fibrosis index***

The Pediatric NAFLD fibrosis index (PNFI) was the first noninvasive fibrosis score created for children. Developed by Nobili *et al*[145] in a study of 136 children with biopsy-proven fibrosis, the PNFI uses age, waist circumference, and triglycerides to determine the degree of fibrosis. The PNFI had an AUROC of 0.85 in predicting liver fibrosis (≥ F1) and PNFI ≥ 9 had a PPV of 98.5%. However, the AUROC dropped to 0.41 in predicting ≥ F2 fibrosis in an external validation of the PNFI in a cohort of Korean children[141]. Interestingly, Alkhouri *et al*[108] found that PNFI had an AUROC of 0.747 in predicting the presence of clinically significant fibrosis (≥ F2) in children with NAFLD. A cutoff of PNFI > 8.2 provided 97% accuracy in predicting early fibrosis (F0–F1) and could be used to rule out patients with significant fibrosis. When combined with data for TE, the algorithm could predict the presence or absence of clinically significant fibrosis in 98% of children with NAFLD.

***PNFS***

The PNFS was developed in 2014 by Alkhouri *et al*[146] from a cohort of 242 children with biopsy-proven NAFLD. The PNFS uses ALT, alkaline phosphatase, platelet counts and GGT and was found to have an AUROC of 0.74 for the detection of advanced fibrosis (≥ F3). At a cutoff of 26%, PNFS had a sensitivity of 31%, specificity 92%, PPV 41% and NPV 88%. This scoring algorithm was found to be superior to APRI, FIB-4 and the NAFLD Activity Score (NAS). PNFS has not been validated by outside groups in the pediatric NAFLD population since being developed.

***Enhanced liver fibrosis***

The enhanced liver fibrosis (ELF) test was first characterized and validated in a cohort of adults with chronic liver disease[147]. ELF has been studied extensively in adults and shown to be an excellent marker of fibrosis in adults with chronic liver disease[76]. It is calculated using three serum biomarkers: HA, PIIINP, and TIMP1. Interestingly, these three markers have themselves been studied as serological biomarkers of fibrosis in children with NAFLD. In studies of adults with NAFLD/NASH, ELF has been validated and found to have an AUROC of 0.9 in distinguishing severe fibrosis, 0.82 for moderate fibrosis and 0.76 for no fibrosis[76]. In a pediatric study of 112 children with likely NAFLD, ELF was able to accurately predict the stage of fibrosis with an AUROC of 0.92 for any fibrosis (≥ stage 1), 0.92 for moderate-perisinusoidal fibrosis (≥ stage 1b), 0.90 for moderate-portal/periportal fibrosis (≥ stage 1c), and 0.99 for advanced fibrosis (≥ stage 3). The ELF test was found to have a high accuracy in predicting any fibrosis, with an AUROC of 0.92 (at an optimal cutoff value of 9.28, it had sensitivity of 88%, specificity of 81%, PPV of 90% and NPV of 77%)[148]. A later study by Alkhouri *et al*[149] found a lower optimal cutoff of 8.49 (sensitivity 76.9%, specificity 97%). Interestingly, when PNFI and ELF were combined, they were able to predict the presence or absence of fibrosis in 86.4% of children with NAFLD. It is important to note that ELF uses biomarkers that are not commonly available in a blood biochemistry panel, and therefore, potentially is less accessible than other fibrosis scores. Another study by Gawrieh *et al*[150] evaluated the relationship of the ELF score with histology in children from the Treatment of NAFLD In Children trial and found that ELF was significantly associated with severity of fibrosis at baseline and 2 years after treatment. In determining the presence of any fibrosis (≥ F1), ELF has an AUROC of 0.60, for ≥ F2 AUROC was 0.70, and for ≥ F3 AUROC was 0.79. ELF requires further validation in the pediatric NAFLD population prior to being implemented in clinical practice.

**CONCLUSION**

Pediatric NAFLD has increased in prevalence over the past decade in conjunction with the obesity epidemic. An early diagnosis of NAFLD, NASH, and fibrosis play a large part in preventing disease progression and tailoring management for patients. Therefore, it is very important that we develop and validate noninvasive methods of diagnosis for children with NAFLD.

Adiponectin, IL-1β, IL-6, and IL-17 all have strong diagnostic accuracy in identifying NAFLD in children with obesity with AUROC values exceeding 0.90. CK18 is extensively studied in children and appears to be the most promising serology-based NIT for the diagnosis of pediatric NASH. Given that adding CK18 to individual biomarkers, such as Ang-2 or CatD, significantly increases their diagnostic abilities, it stands to reason that further research into composite algorithms including CK18 will generate productive results. While select serological biomarkers (*e.g.* PIIINP and HA) have AUROCs > 0.90 in predicting advanced fibrosis, most of these serological markers perform poorly in detecting the presence of mild-moderate fibrosis, highlighting the need for further research in this area.

With regard to imaging, MRI-PDFF is superior to ultrasound-based CAP for the diagnosis of steatosis. While TE has excellent performance in differentiating stages of fibrosis, MRI-based methods that have weaker performance have an advantage when it comes to visualization of the liver both in terms of penetration depth and field of view. This is especially important given the rising number of children who have both NAFLD and (morbid) obesity. Future research should focus particularly on better noninvasive imaging modalities for the diagnosis of pediatric NASH, with excellent performance in diverse pediatric populations.

Currently, clinical practice in adults oftentimes utilizes a two-step screening approach for NAFLD prior to considering liver biopsy. In children with NAFLD, one could consider screening with ALT levels first in children with risk factors and, if above the gender-specific upper limit of normal, proceed to subsequent elastography with fat quantification through MRI-PDFF or ultrasound-based CAP measures. MRI-based methods would be preferred over ultrasound-based techniques in obese patients given the higher success rate. Clinicians would then proceed with liver biopsy if imaging reveals concerning findings and/or if ALT levels are persistently elevated > 80 U/L. Further studies are warranted to determine the cost-effectiveness of widespread implementation of elastography in the work-up of pediatric NAFLD.

**REFERENCES**

1 **Aggarwal A**, Puri K, Thangada S, Zein N, Alkhouri N. Nonalcoholic fatty liver disease in children: recent practice guidelines, where do they take us? *Curr Pediatr Rev* 2014; **10**: 151-161 [PMID: 25088269 DOI: 10.2174/157339631130900007]

2 **Yu EL**, Schwimmer JB. Epidemiology of Pediatric Nonalcoholic Fatty Liver Disease. *Clin Liver Dis (Hoboken)* 2021; **17**: 196-199 [PMID: 33868665 DOI: 10.1002/cld.1027]

3 **Schwimmer JB**, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics* 2006; **118**: 1388-1393 [PMID: 17015527 DOI: 10.1542/peds.2006-1212]

4 **Anderson EL**, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. *PLoS One* 2015; **10**: e0140908 [PMID: 26512983 DOI: 10.1371/journal.pone.0140908]

5 **Hartmann P**, Schnabl B. Risk factors for progression of and treatment options for NAFLD in children. *Clin Liver Dis (Hoboken)* 2018; **11**: 11-15 [PMID: 29629177 DOI: 10.1002/cld.685]

6 **Vos MB**, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, Mouzaki M, Sathya P, Schwimmer JB, Sundaram SS, Xanthakos SA. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). *J Pediatr Gastroenterol Nutr* 2017; **64**: 319-334 [PMID: 28107283 DOI: 10.1097/MPG.0000000000001482]

7 **Schwimmer JB**, Newton KP, Awai HI, Choi LJ, Garcia MA, Ellis LL, Vanderwall K, Fontanesi J. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2013; **38**: 1267-1277 [PMID: 24117728 DOI: 10.1111/apt.12518]

8 **Ando Y**, Jou JH. Nonalcoholic Fatty Liver Disease and Recent Guideline Updates. *Clin Liver Dis (Hoboken)* 2021; **17**: 23-28 [PMID: 33552482 DOI: 10.1002/cld.1045]

9 **Vieira Barbosa J**, Lai M. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. *Hepatol Commun* 2021; **5**: 158-167 [PMID: 33553966 DOI: 10.1002/hep4.1618]

10 **Kleiner DE**, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005; **41**: 1313-1321 [PMID: 15915461 DOI: 10.1002/hep.20701]

11 **Bedossa P**, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, Tordjman J, Clement K. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. *Hepatology* 2012; **56**: 1751-1759 [PMID: 22707395 DOI: 10.1002/hep.25889]

12 **Angulo P**, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2015; **149**: 389-97.e10 [PMID: 25935633 DOI: 10.1053/j.gastro.2015.04.043]

13 **Mu W**, Cheng XF, Liu Y, Lv QZ, Liu GL, Zhang JG, Li XY. Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues. *Front Pharmacol* 2018; **9**: 1566 [PMID: 30692925 DOI: 10.3389/fphar.2018.01566]

14 **Gao B**, Tsukamoto H. Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe? *Gastroenterology* 2016; **150**: 1704-1709 [PMID: 26826669 DOI: 10.1053/j.gastro.2016.01.025]

15 **Tanaka T**, Narazaki M, Kishimoto T. Interleukin (IL-6) Immunotherapy. *Cold Spring Harb Perspect Biol* 2018; **10** [PMID: 28778870 DOI: 10.1101/cshperspect.a028456]

16 **Li Y**, Wei C, Xu H, Jia J, Wei Z, Guo R, Jia Y, Wu Y, Li Y, Qi X, Li Z, Gao X. The Immunoregulation of Th17 in Host against Intracellular Bacterial Infection. *Mediators Inflamm* 2018; **2018**: 6587296 [PMID: 29743811 DOI: 10.1155/2018/6587296]

17 **Harley IT**, Stankiewicz TE, Giles DA, Softic S, Flick LM, Cappelletti M, Sheridan R, Xanthakos SA, Steinbrecher KA, Sartor RB, Kohli R, Karp CL, Divanovic S. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. *Hepatology* 2014; **59**: 1830-1839 [PMID: 24115079 DOI: 10.1002/hep.26746]

18 **Duan Y**, Luo J, Pan X, Wei J, Xiao X, Li J, Luo M. Association between inflammatory markers and non-alcoholic fatty liver disease in obese children. *Front Public Health* 2022; **10**: 991393 [PMID: 36530698 DOI: 10.3389/fpubh.2022.991393]

19 **Flisiak-Jackiewicz M**, Bobrus-Chociej A, Tarasów E, Wojtkowska M, Białokoz-Kalinowska I, Lebensztejn DM. Predictive Role of Interleukin-18 in Liver Steatosis in Obese Children. *Can J Gastroenterol Hepatol* 2018; **2018**: 3870454 [PMID: 29854715 DOI: 10.1155/2018/3870454]

20 **Dinarello CA**. Interleukin-18 and the pathogenesis of inflammatory diseases. *Semin Nephrol* 2007; **27**: 98-114 [PMID: 17336692 DOI: 10.1016/j.semnephrol.2006.09.013]

21 **Skurk T**, Kolb H, Müller-Scholze S, Röhrig K, Hauner H, Herder C. The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. *Eur J Endocrinol* 2005; **152**: 863-868 [PMID: 15941925 DOI: 10.1530/eje.1.01897]

22 **Finelli C**, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? *World J Gastroenterol* 2013; **19**: 802-812 [PMID: 23430039 DOI: 10.3748/wjg.v19.i6.802]

23 **Bugianesi E**, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. *J Clin Endocrinol Metab* 2005; **90**: 3498-3504 [PMID: 15797948 DOI: 10.1210/jc.2004-2240]

24 **Boyraz M**, Cekmez F, Karaoglu A, Cinaz P, Durak M, Bideci A. Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease. *Biomark Med* 2013; **7**: 737-745 [PMID: 24044566 DOI: 10.2217/bmm.13.13]

25 **Mohamed AA**, Sabry S, Abdallah AM, Elazeem NAA, Refaey D, Algebaly HAF, Fath GAE, Omar H. Circulating adipokines in children with nonalcoholic fatty liver disease: possible noninvasive diagnostic markers. *Ann Gastroenterol* 2017; **30**: 457-463 [PMID: 28655985 DOI: 10.20524/aog.2017.0148]

26 **Yamauchi T**, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. *Nature* 2003; **423**: 762-769 [PMID: 12802337 DOI: 10.1038/nature01705]

27 **Yamauchi T**, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. *Nat Med* 2001; **7**: 941-946 [PMID: 11479627 DOI: 10.1038/90984]

28 **Aksoy GK**, Artan R, Aksoy C, Özdem S, Atalay A, Yılmaz A. Role of Soluble Adiponectin Receptor 2 in Non-Alcoholic Fatty Liver Disease in Children. *Pediatr Gastroenterol Hepatol Nutr* 2019; **22**: 470-478 [PMID: 31555572 DOI: 10.5223/pghn.2019.22.5.470]

29 **Musso G**, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. *Ann Med* 2011; **43**: 617-649 [PMID: 21039302 DOI: 10.3109/07853890.2010.518623]

30 **Nishimura T**, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. *Biochim Biophys Acta* 2000; **1492**: 203-206 [PMID: 10858549 DOI: 10.1016/s0167-4781(00)00067-1]

31 **Lebensztejn DM**, Flisiak-Jackiewicz M, Białokoz-Kalinowska I, Bobrus-Chociej A, Kowalska I. Hepatokines and non-alcoholic fatty liver disease. *Acta Biochim Pol* 2016; **63**: 459-467 [PMID: 27262842 DOI: 10.18388/abp.2016\_1252]

32 **Yilmaz Y**, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. *Eur J Clin Invest* 2010; **40**: 887-892 [PMID: 20624171 DOI: 10.1111/j.1365-2362.2010.02338.x]

33 **Li H**, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, Jia W. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. *J Hepatol* 2010; **53**: 934-940 [PMID: 20675007 DOI: 10.1016/j.jhep.2010.05.018]

34 **Reinehr T**, Woelfle J, Wunsch R, Roth CL. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. *J Clin Endocrinol Metab* 2012; **97**: 2143-2150 [PMID: 22438225 DOI: 10.1210/jc.2012-1221]

35 **Giannini C**, Feldstein AE, Santoro N, Kim G, Kursawe R, Pierpont B, Caprio S. Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. *J Clin Endocrinol Metab* 2013; **98**: 2993-3000 [PMID: 23626003 DOI: 10.1210/jc.2013-1250]

36 **Alisi A**, Ceccarelli S, Panera N, Prono F, Petrini S, De Stefanis C, Pezzullo M, Tozzi A, Villani A, Bedogni G, Nobili V. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. *PLoS One* 2013; **8**: e67160 [PMID: 23840612 DOI: 10.1371/journal.pone.0067160]

37 **Liu X**, Zhang P, Martin RC, Cui G, Wang G, Tan Y, Cai L, Lv G, Li Y. Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice. *Am J Cancer Res* 2016; **6**: 1011-1025 [PMID: 27293995]

38 **Hua MC**, Huang JL, Hu CC, Yao TC, Lai MW. Including Fibroblast Growth Factor-21 in Combined Biomarker Panels Improves Predictions of Liver Steatosis Severity in Children. *Front Pediatr* 2019; **7**: 420 [PMID: 31750276 DOI: 10.3389/fped.2019.00420]

39 **Colica C**, Abenavoli L. Resistin Levels in Non-alcoholic Fatty Liver Disease Pathogenesis. *J Transl Int Med* 2018; **6**: 52-53 [PMID: 29607306 DOI: 10.2478/jtim-2018-0011]

40 **Tsutsumi C**, Okuno M, Tannous L, Piantedosi R, Allan M, Goodman DS, Blaner WS. Retinoids and retinoid-binding protein expression in rat adipocytes. *J Biol Chem* 1992; **267**: 1805-1810 [PMID: 1370481]

41 **O'Byrne SM**, Blaner WS. Retinol and retinyl esters: biochemistry and physiology. *J Lipid Res* 2013; **54**: 1731-1743 [PMID: 23625372 DOI: 10.1194/jlr.R037648]

42 **Seo JA**, Kim NH, Park SY, Kim HY, Ryu OH, Lee KW, Lee J, Kim DL, Choi KM, Baik SH, Choi DS, Kim SG. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. *Clin Endocrinol (Oxf)* 2008; **68**: 555-560 [PMID: 17941908 DOI: 10.1111/j.1365-2265.2007.03072.x]

43 **Takahashi M**, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitazawa R, Iida K, Okimura Y, Kaji H, Kitazawa S, Kasuga M, Chihara K. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. *FEBS Lett* 2008; **582**: 573-578 [PMID: 18242188 DOI: 10.1016/j.febslet.2008.01.023]

44 **Panera N**, Della Corte C, Crudele A, Stronati L, Nobili V, Alisi A. Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. *Expert Rev Gastroenterol Hepatol* 2016; **10**: 393-403 [PMID: 26654761 DOI: 10.1586/17474124.2016.1110485]

45 **Bozaoglu K**, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. *Endocrinology* 2007; **148**: 4687-4694 [PMID: 17640997 DOI: 10.1210/en.2007-0175]

46 **Kłusek-Oksiuta M**, Bialokoz-Kalinowska I, Tarasów E, Wojtkowska M, Werpachowska I, Lebensztejn DM. Chemerin as a novel non-invasive serum marker of intrahepatic lipid content in obese children. *Ital J Pediatr* 2014; **40**: 84 [PMID: 25399407 DOI: 10.1186/s13052-014-0084-4]

47 **Elkabany ZA**, Hamza RT, Ismail EAR, Elsharkawy A, Yosry A, Musa S, Khalaf MA, Elgawesh RM, Esmat G. Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter. *Eur J Gastroenterol Hepatol* 2020; **32**: 1008-1016 [PMID: 31834057 DOI: 10.1097/MEG.0000000000001608]

48 **Brown JE**, Onyango DJ, Ramanjaneya M, Conner AC, Patel ST, Dunmore SJ, Randeva HS. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. *J Mol Endocrinol* 2010; **44**: 171-178 [PMID: 19906834 DOI: 10.1677/JME-09-0071]

49 **Genc H**, Dogru T, Kara M, Tapan S, Ercin CN, Acikel C, Karslioglu Y, Bagci S. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. *Ann Hepatol* 2013; **12**: 548-555 [PMID: 23813132]

50 **Nourbakhsh M**, Nourbakhsh M, Gholinejad Z, Razzaghy-Azar M. Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome. *Scand J Clin Lab Invest* 2015; **75**: 183-188 [PMID: 25723377 DOI: 10.3109/00365513.2014.1003594]

51 **Hartmann P**, Schnabl B. Inexpensive, Accurate, and Stable Method to Quantitate Blood Alanine Aminotransferase (ALT) Levels. *Methods Protoc* 2022; **5** [PMID: 36287053 DOI: 10.3390/mps5050081]

52 **Manco M**, Alisi A, Nobili V. Risk of severe liver disease in NAFLD with normal ALT levels: a pediatric report. *Hepatology* 2008; **48**: 2087-2088; author reply 2088 [PMID: 18980229 DOI: 10.1002/hep.22631]

53 **Molleston JP**, Schwimmer JB, Yates KP, Murray KF, Cummings OW, Lavine JE, Brunt EM, Scheimann AO, Unalp-Arida A; NASH Clinical Research Network. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. *J Pediatr* 2014; **164**: 707-713.e3 [PMID: 24360992 DOI: 10.1016/j.jpeds.2013.10.071]

54 **Arsik I**, Frediani JK, Frezza D, Chen W, Ayer T, Keskinocak P, Jin R, Konomi JV, Barlow SE, Xanthakos SA, Lavine JE, Vos MB. Alanine Aminotransferase as a Monitoring Biomarker in Children with Nonalcoholic Fatty Liver Disease: A Secondary Analysis Using TONIC Trial Data. *Children (Basel)* 2018; **5** [PMID: 29799476 DOI: 10.3390/children5060064]

55 **Miyao M**, Kotani H, Ishida T, Kawai C, Manabe S, Abiru H, Tamaki K. Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression. *Lab Invest* 2015; **95**: 1130-1144 [PMID: 26214582 DOI: 10.1038/labinvest.2015.95]

56 **Lefere S**, Van de Velde F, Hoorens A, Raevens S, Van Campenhout S, Vandierendonck A, Neyt S, Vandeghinste B, Vanhove C, Debbaut C, Verhelst X, Van Dorpe J, Van Steenkiste C, Casteleyn C, Lapauw B, Van Vlierberghe H, Geerts A, Devisscher L. Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease. *Hepatology* 2019; **69**: 1087-1104 [PMID: 30259536 DOI: 10.1002/hep.30294]

57 **Manco M**, Panera N, Crudele A, Braghini MR, Bianchi M, Comparcola D, De Vito R, Maggiore G, Alisi A. Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease. *Pediatr Res* 2022; **91**: 1781-1786 [PMID: 34331020 DOI: 10.1038/s41390-021-01666-5]

58 **Cave M**, Falkner KC, Henry L, Costello B, Gregory B, McClain CJ. Serum cytokeratin 18 and cytokine elevations suggest a high prevalence of occupational liver disease in highly exposed elastomer/polymer workers. *J Occup Environ Med* 2011; **53**: 1128-1133 [PMID: 21915069 DOI: 10.1097/JOM.0b013e31822cfd68]

59 **Hartmann P**, Lang S, Zeng S, Duan Y, Zhang X, Wang Y, Bondareva M, Kruglov A, Fouts DE, Stärkel P, Schnabl B. Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder. *Front Physiol* 2021; **12**: 699253 [PMID: 34349667 DOI: 10.3389/fphys.2021.699253]

60 **Diab DL**, Yerian L, Schauer P, Kashyap SR, Lopez R, Hazen SL, Feldstein AE. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. *Clin Gastroenterol Hepatol* 2008; **6**: 1249-1254 [PMID: 18995215 DOI: 10.1016/j.cgh.2008.07.016]

61 **Yilmaz Y**, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. *World J Gastroenterol* 2007; **13**: 837-844 [PMID: 17352011 DOI: 10.3748/wjg.v13.i6.837]

62 **Anty R**, Iannelli A, Patouraux S, Bonnafous S, Lavallard VJ, Senni-Buratti M, Amor IB, Staccini-Myx A, Saint-Paul MC, Berthier F, Huet PM, Le Marchand-Brustel Y, Gugenheim J, Gual P, Tran A. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. *Aliment Pharmacol Ther* 2010; **32**: 1315-1322 [PMID: 21050233 DOI: 10.1111/j.1365-2036.2010.04480.x]

63 **Lee J**, Vali Y, Boursier J, Duffin K, Verheij J, Brosnan MJ, Zwinderman K, Anstee QM, Bossuyt PM, Zafarmand MH. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. *PLoS One* 2020; **15**: e0238717 [PMID: 32915852 DOI: 10.1371/journal.pone.0238717]

64 **Feldstein AE**, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. *Hepatology* 2009; **50**: 1072-1078 [PMID: 19585618 DOI: 10.1002/hep.23050]

65 **Vos MB**, Barve S, Joshi-Barve S, Carew JD, Whitington PF, McClain CJ. Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. *J Pediatr Gastroenterol Nutr* 2008; **47**: 481-485 [PMID: 18852641 DOI: 10.1097/MPG.0b013e31817e2bfb]

66 **Feldstein AE**, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. *Am J Gastroenterol* 2013; **108**: 1526-1531 [PMID: 23752877 DOI: 10.1038/ajg.2013.168]

67 **Fitzpatrick E**, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, Dhawan A. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. *J Pediatr Gastroenterol Nutr* 2010; **51**: 500-506 [PMID: 20808246 DOI: 10.1097/MPG.0b013e3181e376be]

68 **Vuppalanchi R**, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J, Chalasani N. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2014; **12**: 2121-30.e1-2 [PMID: 24846279 DOI: 10.1016/j.cgh.2014.05.010]

69 **Uhlén M**, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F. Proteomics. Tissue-based map of the human proteome. *Science* 2015; **347**: 1260419 [PMID: 25613900 DOI: 10.1126/science.1260419]

70 **Walenbergh SM**, Houben T, Hendrikx T, Jeurissen ML, van Gorp PJ, Vreugdenhil AC, Adriaanse MP, Buurman WA, Hofker MH, Mosca A, Lindsey PJ, Alisi A, Liccardo D, Panera N, Koek GH, Nobili V, Shiri-Sverdlov R. Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation. *Am J Gastroenterol* 2015; **110**: 462-470 [PMID: 25732418 DOI: 10.1038/ajg.2015.29]

71 **Walenbergh SM**, Houben T, Rensen SS, Bieghs V, Hendrikx T, van Gorp PJ, Oligschlaeger Y, Jeurissen ML, Gijbels MJ, Buurman WA, Vreugdenhil AC, Greve JW, Plat J, Hofker MH, Kalhan S, Pihlajamäki J, Lindsey P, Koek GH, Shiri-Sverdlov R. Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention. *Sci Rep* 2016; **6**: 38278 [PMID: 27922112 DOI: 10.1038/srep38278]

72 **Perito ER**, Ajmera V, Bass NM, Rosenthal P, Lavine JE, Schwimmer JB, Yates KP, Diehl AM, Molleston JP, Murray KF, Scheimann A, Gill R, Glidden D, Aouizerat B. Association Between Cytokines and Liver Histology in Children with Nonalcoholic Fatty Liver Disease. *Hepatol Commun* 2017; **1**: 609-622 [PMID: 29130075 DOI: 10.1002/hep4.1068]

73 **Ekstedt M**, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* 2015; **61**: 1547-1554 [PMID: 25125077 DOI: 10.1002/hep.27368]

74 **Poynard T**, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997; **349**: 825-832 [PMID: 9121257 DOI: 10.1016/S0140-6736(96)07642-8]

75 **Guéchot J**, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. *Clin Chem* 1996; **42**: 558-563 [PMID: 8605673 DOI: 10.1093/clinchem/42.4.558]

76 **Guha IN**, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. *Hepatology* 2008; **47**: 455-460 [PMID: 18038452 DOI: 10.1002/hep.21984]

77 **Miele L**, Forgione A, La Torre G, Vero V, Cefalo C, Racco S, Vellone VG, Vecchio FM, Gasbarrini G, Rapaccini GL, Neuman MG, Grieco A. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. *Transl Res* 2009; **154**: 194-201 [PMID: 19766963 DOI: 10.1016/j.trsl.2009.06.007]

78 **Suzuki A**, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. *Liver Int* 2005; **25**: 779-786 [PMID: 15998429 DOI: 10.1111/j.1478-3231.2005.01064.x]

79 **Nobili V**, Alisi A, Torre G, De Vito R, Pietrobattista A, Morino G, De Ville De Goyet J, Bedogni G, Pinzani M. Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. *Transl Res* 2010; **156**: 229-234 [PMID: 20875899 DOI: 10.1016/j.trsl.2010.05.008]

80 **Lebensztejn DM**, Wierzbicka A, Socha P, Pronicki M, Skiba E, Werpachowska I, Kaczmarski M. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. *Acta Biochim Pol* 2011; **58**: 563-566 [PMID: 22140659]

81 **Karsdal MA**, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, Surabattula R, Villesen IF, Luo Y, Shevell D, Gudmann NS, Nielsen MJ, George J, Christian R, Leeming DJ, Schuppan D. Collagen biology and non-invasive biomarkers of liver fibrosis. *Liver Int* 2020; **40**: 736-750 [PMID: 31997561 DOI: 10.1111/liv.14390]

82 **Daniels SJ**, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, Karsdal MA, Grove JI, Neil Guha I, Kawaguchi T, Torimura T, McLeod D, Akiba J, Kaye P, de Boer B, Aithal GP, Adams LA, George J. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. *Hepatology* 2019; **69**: 1075-1086 [PMID: 30014517 DOI: 10.1002/hep.30163]

83 **Cohen CC**, Castillo-Leon E, Farris AB, Caltharp SA, Cleeton RL, Sinclair EM, Shevell DE, Karsdal MA, Nielsen MJF, Leeming DJ, Vos MB. PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD. *Hepatol Commun* 2021; **5**: 1860-1872 [PMID: 34558828 DOI: 10.1002/hep4.1766]

84 **Mandelia C**, Collyer E, Mansoor S, Lopez R, Lappe S, Nobili V, Alkhouri N. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease. *J Pediatr Gastroenterol Nutr* 2016; **63**: 181-187 [PMID: 26835904 DOI: 10.1097/MPG.0000000000001136]

85 **Johansen JS**, Christoffersen P, Møller S, Price PA, Henriksen JH, Garbarsch C, Bendtsen F. Serum YKL-40 is increased in patients with hepatic fibrosis. *J Hepatol* 2000; **32**: 911-920 [PMID: 10898311 DOI: 10.1016/S0168-8278(00)80095-1]

86 **Mantzoros CS**. The role of leptin in human obesity and disease: a review of current evidence. *Ann Intern Med* 1999; **130**: 671-680 [PMID: 10215564 DOI: 10.7326/0003-4819-130-8-199904200-00014]

87 **Mantzoros CS**, Moschos SJ. Leptin: in search of role(s) in human physiology and pathophysiology. *Clin Endocrinol (Oxf)* 1998; **49**: 551-567 [PMID: 10197068 DOI: 10.1046/j.1365-2265.1998.00571.x]

88 **Tsochatzis EA**, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. *Mediators Inflamm* 2009; **2009**: 831670 [PMID: 19753129 DOI: 10.1155/2009/831670]

89 **Leclercq IA**, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. *J Hepatol* 2002; **37**: 206-213 [PMID: 12127425 DOI: 10.1016/S0168-8278(02)00102-2]

90 **Ikejima K**, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. *Gastroenterology* 2002; **122**: 1399-1410 [PMID: 11984526 DOI: 10.1053/gast.2002.32995]

91 **Marra F**. Leptin and liver tissue repair: do rodent models provide the answers? *J Hepatol* 2007; **46**: 12-18 [PMID: 17112630 DOI: 10.1016/j.jhep.2006.10.002]

92 **Qamar A**, Sheikh SZ, Masud A, Jhandier MN, Inayat IB, Hakim W, Mehal WZ. In vitro and in vivo protection of stellate cells from apoptosis by leptin. *Dig Dis Sci* 2006; **51**: 1697-1705 [PMID: 16957995 DOI: 10.1007/s10620-006-9244-8]

93 **Polyzos SA**, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: a narrative review. *Metabolism* 2015; **64**: 60-78 [PMID: 25456097 DOI: 10.1016/j.metabol.2014.10.012]

94 **Rotundo L**, Persaud A, Feurdean M, Ahlawat S, Kim HS. The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study. *Clin Mol Hepatol* 2018; **24**: 392-401 [PMID: 30068065 DOI: 10.3350/cmh.2018.0011]

95 **Manco M**, Marcellini M, Giannone G, Nobili V. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. *Am J Clin Pathol* 2007; **127**: 954-960 [PMID: 17509993 DOI: 10.1309/6VJ4DWGYDU0XYJ8Q]

96 **Brandt S**, von Schnurbein J, Denzer C, Kratzer W, Wabitsch M. Lower Circulating Leptin Levels Are Related to Non-Alcoholic Fatty Liver Disease in Children With Obesity. *Front Endocrinol (Lausanne)* 2022; **13**: 881982 [PMID: 35677722 DOI: 10.3389/fendo.2022.881982]

97 **Nobili V**, Manco M, Ciampalini P, Diciommo V, Devito R, Piemonte F, Comparcola D, Guidi R, Marcellini M. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. *Eur J Endocrinol* 2006; **155**: 735-743 [PMID: 17062890 DOI: 10.1530/eje.1.02288]

98 **Frei A**, Zimmermann A, Weigand K. The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. *Hepatology* 1984; **4**: 830-834 [PMID: 6479851 DOI: 10.1002/hep.1840040505]

99 **Hamza RT**, Ahmed AY, Rezk DG, Hamed AI. Dietary fructose intake in obese children and adolescents: relation to procollagen type III N-terminal peptide (P3NP) and non-alcoholic fatty liver disease. *J Pediatr Endocrinol Metab* 2016; **29**: 1345-1352 [PMID: 27442361 DOI: 10.1515/jpem-2016-0015]

100 **Tanwar S**, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. *Hepatology* 2013; **57**: 103-111 [PMID: 22930399 DOI: 10.1002/hep.26030]

101 **Mosca A**, Comparcola D, Romito I, Mantovani A, Nobili V, Byrne CD, Alisi A, Targher G. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease. *Liver Int* 2019; **39**: 2317-2329 [PMID: 31436362 DOI: 10.1111/liv.14225]

102 **Afdhal NH**. Fibroscan (transient elastography) for the measurement of liver fibrosis. *Gastroenterol Hepatol (N Y)* 2012; **8**: 605-607 [PMID: 23483859]

103 **Sasso M**, Audière S, Kemgang A, Gaouar F, Corpechot C, Chazouillères O, Fournier C, Golsztejn O, Prince S, Menu Y, Sandrin L, Miette V. Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy. *Ultrasound Med Biol* 2016; **42**: 92-103 [PMID: 26386476 DOI: 10.1016/j.ultrasmedbio.2015.08.008]

104 **Kwon YD**, Ko KO, Lim JW, Cheon EJ, Song YH, Yoon JM. Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis. *J Korean Med Sci* 2019; **34**: e165 [PMID: 31197983 DOI: 10.3346/jkms.2019.34.e165]

105 **Chaidez A**, Pan Z, Sundaram SS, Boster J, Lovell M, Sokol RJ, Mack CL. The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan-aspartate aminotransferase to predict severity of liver disease in children. *Hepatol Commun* 2022; **6**: 3015-3023 [PMID: 36069338 DOI: 10.1002/hep4.1983]

106 **Yang L**, Zhu Y, Zhou L, Yin H, Lin Y, Wu G. Transient Elastography in the Diagnosis of Pediatric Non-alcoholic Fatty Liver Disease and Its Subtypes. *Front Pediatr* 2022; **10**: 808997 [PMID: 35433553 DOI: 10.3389/fped.2022.808997]

107 **Nobili V**, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, Fruhwirth R, Marcellini M, Pinzani M. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. *Hepatology* 2008; **48**: 442-448 [PMID: 18563842 DOI: 10.1002/hep.22376]

108 **Alkhouri N**, Sedki E, Alisi A, Lopez R, Pinzani M, Feldstein AE, Nobili V. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. *Liver Int* 2013; **33**: 79-85 [PMID: 23146095 DOI: 10.1111/liv.12024]

109 **Liu H**, Fu J, Hong R, Liu L, Li F. Acoustic Radiation Force Impulse Elastography for the Non-Invasive Evaluation of Hepatic Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review & Meta-Analysis. *PLoS One* 2015; **10**: e0127782 [PMID: 26131717 DOI: 10.1371/journal.pone.0127782]

110 **Kamble R**, Sodhi KS, Thapa BR, Saxena AK, Bhatia A, Dayal D, Khandelwal N. Liver acoustic radiation force impulse (ARFI) in childhood obesity: comparison and correlation with biochemical markers. *J Ultrasound* 2017; **20**: 33-42 [PMID: 28298942 DOI: 10.1007/s40477-016-0229-y]

111 **Berná-Serna JD**, Sánchez-Jiménez R, Velázquez-Marín F, Sainz de Baranda P, Guzmán-Aroca F, Fernández-Hernández C, Doménech-Abellán E, Abellán-Rivero D, Ruiz-Merino G, Madrid-Conesa J, Canteras-Jordana M. Acoustic radiation force impulse imaging for detection of liver fibrosis in overweight and obese children. *Acta Radiol* 2018; **59**: 247-253 [PMID: 28475023 DOI: 10.1177/0284185117707359]

112 **Kim JR**, Suh CH, Yoon HM, Lee JS, Cho YA, Jung AY. The diagnostic performance of shear-wave elastography for liver fibrosis in children and adolescents: A systematic review and diagnostic meta-analysis. *Eur Radiol* 2018; **28**: 1175-1186 [PMID: 29018925 DOI: 10.1007/s00330-017-5078-3]

113 **Noruegas MJ**, Matos H, Gonçalves I, Cipriano MA, Sanches C. Acoustic radiation force impulse-imaging in the assessment of liver fibrosis in children. *Pediatr Radiol* 2012; **42**: 201-204 [PMID: 22002843 DOI: 10.1007/s00247-011-2257-2]

114 **Reeder SB**, Cruite I, Hamilton G, Sirlin CB. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. *J Magn Reson Imaging* 2011; **34**: 729-749 [PMID: 22025886 DOI: 10.1002/jmri.22580]

115 **Yokoo T**, Serai SD, Pirasteh A, Bashir MR, Hamilton G, Hernando D, Hu HH, Hetterich H, Kühn JP, Kukuk GM, Loomba R, Middleton MS, Obuchowski NA, Song JS, Tang A, Wu X, Reeder SB, Sirlin CB; RSNA-QIBA PDFF Biomarker Committee. Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis. *Radiology* 2018; **286**: 486-498 [PMID: 28892458 DOI: 10.1148/radiol.2017170550]

116 **Tang A**, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, Clark L, Hooker J, Chavez T, Ang BD, Middleton MS, Peterson M, Loomba R, Sirlin CB. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. *Radiology* 2015; **274**: 416-425 [PMID: 25247408 DOI: 10.1148/radiol.14140754]

117 **Tang A**, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, Gamst AC, Middleton M, Brunt EM, Loomba R, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. *Radiology* 2013; **267**: 422-431 [PMID: 23382291 DOI: 10.1148/radiol.12120896]

118 **Neuschwander-Tetri BA**, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet* 2015; **385**: 956-965 [PMID: 25468160 DOI: 10.1016/S0140-6736(14)61933-4]

119 **Middleton MS**, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, Brunt EM, Kleiner DE, Doo E, Van Natta ML, Lavine JE, Neuschwander-Tetri BA, Sanyal A, Loomba R, Sirlin CB; NASH Clinical Research Network. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. *Gastroenterology* 2017; **153**: 753-761 [PMID: 28624576 DOI: 10.1053/j.gastro.2017.06.005]

120 **Schwimmer JB**, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN, Lam J, Hooker JC, Hamilton G, Fontanesi J, Sirlin CB. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. *Hepatology* 2015; **61**: 1887-1895 [PMID: 25529941 DOI: 10.1002/hep.27666]

121 **Middleton MS**, Van Natta ML, Heba ER, Alazraki A, Trout AT, Masand P, Brunt EM, Kleiner DE, Doo E, Tonascia J, Lavine JE, Shen W, Hamilton G, Schwimmer JB, Sirlin CB; NASH Clinical Research Network. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. *Hepatology* 2018; **67**: 858-872 [PMID: 29028128 DOI: 10.1002/hep.29596]

122 **Di Martino M**, Pacifico L, Bezzi M, Di Miscio R, Sacconi B, Chiesa C, Catalano C. Comparison of magnetic resonance spectroscopy, proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents. *World J Gastroenterol* 2016; **22**: 8812-8819 [PMID: 27818597 DOI: 10.3748/wjg.v22.i39.8812]

123 **Zhao YZ**, Gan YG, Zhou JL, Liu JQ, Cao WG, Cheng SM, Bai DM, Wang MZ, Gao FQ, Zhou SM. Accuracy of multi-echo Dixon sequence in quantification of hepatic steatosis in Chinese children and adolescents. *World J Gastroenterol* 2019; **25**: 1513-1523 [PMID: 30948914 DOI: 10.3748/wjg.v25.i12.1513]

124 **Jia S**, Zhao Y, Liu J, Guo X, Chen M, Zhou S, Zhou J. Magnetic Resonance Imaging-Proton Density Fat Fraction vs. Transient Elastography-Controlled Attenuation Parameter in Diagnosing Non-alcoholic Fatty Liver Disease in Children and Adolescents: A Meta-Analysis of Diagnostic Accuracy. *Front Pediatr* 2021; **9**: 784221 [PMID: 35087774 DOI: 10.3389/fped.2021.784221]

125 **Ajmera V**, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. *Mol Metab* 2021; **50**: 101167 [PMID: 33460786 DOI: 10.1016/j.molmet.2021.101167]

126 **Kim TH**, Jeong CW, Jun HY, Lee C, Noh S, Kim JE, Kim S, Yoon KH. Accuracy of proton magnetic resonance for diagnosing non-alcoholic steatohepatitis: a meta-analysis. *Sci Rep* 2019; **9**: 15002 [PMID: 31628409 DOI: 10.1038/s41598-019-51302-w]

127 **Muthupillai R**, Lomas DJ, Rossman PJ, Greenleaf JF, Manduca A, Ehman RL. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. *Science* 1995; **269**: 1854-1857 [PMID: 7569924 DOI: 10.1126/science.7569924]

128 **Venkatesh SK**, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. *J Magn Reson Imaging* 2013; **37**: 544-555 [PMID: 23423795 DOI: 10.1002/jmri.23731]

129 **Yin M**, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, Fidler JL, Ehman RL. Assessment of hepatic fibrosis with magnetic resonance elastography. *Clin Gastroenterol Hepatol* 2007; **5**: 1207-1213.e2 [PMID: 17916548 DOI: 10.1016/j.cgh.2007.06.012]

130 **Huwart L**, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E, Peeters F, ter Beek LC, Rahier J, Sinkus R, Horsmans Y, Van Beers BE. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. *Gastroenterology* 2008; **135**: 32-40 [PMID: 18471441 DOI: 10.1053/j.gastro.2008.03.076]

131 **Singh S**, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, Yin M, Miller FH, Low RN, Hassanein T, Godfrey EM, Asbach P, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. *Eur Radiol* 2016; **26**: 1431-1440 [PMID: 26314479 DOI: 10.1007/s00330-015-3949-z]

132 **Xanthakos SA**, Podberesky DJ, Serai SD, Miles L, King EC, Balistreri WF, Kohli R. Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease. *J Pediatr* 2014; **164**: 186-188 [PMID: 24064151 DOI: 10.1016/j.jpeds.2013.07.050]

133 **Schwimmer JB**, Behling C, Angeles JE, Paiz M, Durelle J, Africa J, Newton KP, Brunt EM, Lavine JE, Abrams SH, Masand P, Krishnamurthy R, Wong K, Ehman RL, Yin M, Glaser KJ, Dzyubak B, Wolfson T, Gamst AC, Hooker J, Haufe W, Schlein A, Hamilton G, Middleton MS, Sirlin CB. Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease. *Hepatology* 2017; **66**: 1474-1485 [PMID: 28493388 DOI: 10.1002/hep.29241]

134 **Trout AT**, Sheridan RM, Serai SD, Xanthakos SA, Su W, Zhang B, Wallihan DB. Diagnostic Performance of MR Elastography for Liver Fibrosis in Children and Young Adults with a Spectrum of Liver Diseases. *Radiology* 2018; **287**: 824-832 [PMID: 29470938 DOI: 10.1148/radiol.2018172099]

135 **Goodman ZD**. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. *J Hepatol* 2007; **47**: 598-607 [PMID: 17692984 DOI: 10.1016/j.jhep.2007.07.006]

136 **Dillman JR**, Trout AT, Costello EN, Serai SD, Bramlage KS, Kohli R, Xanthakos SA. Quantitative Liver MRI-Biopsy Correlation in Pediatric and Young Adult Patients With Nonalcoholic Fatty Liver Disease: Can One Be Used to Predict the Other? *AJR Am J Roentgenol* 2018; **210**: 166-174 [PMID: 29045180 DOI: 10.2214/AJR.17.18446]

137 **Kwon Y**, Kim ES, Choe YH, Kim MJ. Stratification by Non-invasive Biomarkers of Non-alcoholic Fatty Liver Disease in Children. *Front Pediatr* 2022; **10**: 846273 [PMID: 35444966 DOI: 10.3389/fped.2022.846273]

138 **Gudowska-Sawczuk M**, Wrona A, Gruszewska E, Cylwik B, Panasiuk A, Flisiak R, Chrostek L. Serum level of interleukin-6 (IL-6) and N-terminal propeptide of procollagen type I (PINP) in patients with liver diseases. *Scand J Clin Lab Invest* 2018; **78**: 125-130 [PMID: 29272979 DOI: 10.1080/00365513.2017.1420217]

139 **Veidal SS**, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, Karsdal MA. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. *Fibrogenesis Tissue Repair* 2010; **3**: 5 [PMID: 20359335 DOI: 10.1186/1755-1536-3-5]

140 **Mansoor S**, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, Lopez R, Christine CK, Feldstein AE, Alkhouri N. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. *Dig Dis Sci* 2015; **60**: 1440-1447 [PMID: 25540086 DOI: 10.1007/s10620-014-3494-7]

141 **Yang HR**, Kim HR, Kim MJ, Ko JS, Seo JK. Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. *World J Gastroenterol* 2012; **18**: 1525-1530 [PMID: 22509085 DOI: 10.3748/wjg.v18.i13.1525]

142 **Mosca A**, Della Volpe L, Alisi A, Veraldi S, Francalanci P, Maggiore G. Non-Invasive Diagnostic Test for Advanced Fibrosis in Adolescents With Non-Alcoholic Fatty Liver Disease. *Front Pediatr* 2022; **10**: 885576 [PMID: 35558366 DOI: 10.3389/fped.2022.885576]

143 **Ampuero J**, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Zheng MH, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. *Clin Gastroenterol Hepatol* 2020; **18**: 216-225.e5 [PMID: 31195161 DOI: 10.1016/j.cgh.2019.05.051]

144 **Newsome PN**, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. *Lancet Gastroenterol Hepatol* 2020; **5**: 362-373 [PMID: 32027858 DOI: 10.1016/S2468-1253(19)30383-8]

145 **Nobili V**, Alisi A, Vania A, Tiribelli C, Pietrobattista A, Bedogni G. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. *BMC Med* 2009; **7**: 21 [PMID: 19409076 DOI: 10.1186/1741-7015-7-21]

146 **Alkhouri N**, Mansoor S, Giammaria P, Liccardo D, Lopez R, Nobili V. The development of the pediatric NAFLD fibrosis score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease. *PLoS One* 2014; **9**: e104558 [PMID: 25121514 DOI: 10.1371/journal.pone.0104558]

147 **Rosenberg WM**, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ; European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. *Gastroenterology* 2004; **127**: 1704-1713 [PMID: 15578508 DOI: 10.1053/j.gastro.2004.08.052]

148 **Nobili V**, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, Vizzutti F, Pinzani M, Rosenberg WM. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. *Gastroenterology* 2009; **136**: 160-167 [PMID: 18992746 DOI: 10.1053/j.gastro.2008.09.013]

149 **Alkhouri N**, Carter-Kent C, Lopez R, Rosenberg WM, Pinzani M, Bedogni G, Feldstein AE, Nobili V. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. *Clin Gastroenterol Hepatol* 2011; **9**: 150-155 [PMID: 20888433 DOI: 10.1016/j.cgh.2010.09.015]

150 **Gawrieh S**, Harlow KE, Pike F, Yates KP, Wilson LA, Cummings OW, Rosenberg WM, Chalasani N, Molleston JP. Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin. *J Pediatr* 2021; **239**: 161-167.e5 [PMID: 34400208 DOI: 10.1016/j.jpeds.2021.08.012]

**Footnotes**

**Conflict-of-interest statement:** All the authors have no conflicts of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** January 29, 2023

**First decision:** February 23, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Balaban HY, Turkey; Zhang Y, China **S-Editor:** Liu JH **L-Editor:** A **P-Editor:**

**Table 1 Cellular location(s) of synthesis of circulating biomarkers in nonalcoholic fatty liver disease**

|  |  |
| --- | --- |
| **Serological biomarker**  | **Cellular location(s) of synthesis**  |
| Adiponectin | Adipocytes  |
| Adipo R2 | Hepatocytes, skeletal muscle  |
| ALT | Hepatocytes  |
| Ang-2 | Liver sinusoidal endothelial cells  |
| CatD | Lysosomes  |
| Chemerin | Adipocytes  |
| CK18 | Hepatocytes  |
| FGF21 | Hepatocytes  |
| HA | Hepatic stellate cells  |
| IL-1β | Adipocytes  |
| IL-6 | Adipocytes  |
| IL-17 | T helper 17 cells  |
| IL-18 | Macrophages  |
| Leptin | Adipocytes  |
| PIIINP | Released during procollagen processing  |
| PRO-C3 | Extracellular matrix  |
| RBP4 | Adipocytes, Hepatocytes  |
| Resistin | Adipocytes  |
| Visfatin | Adipocytes, Hepatocytes  |

IL: Interleukin; Adipo R2: Soluble adiponectin receptor 2; FGF: Fibroblast growth factor; RBP4: Retinol binding protein 4; ALT: Alanine aminotransferase; Ang-2: Angiopoietin-2; CK18: Cytokeratin 18; CatD: Cathepsin D; HA: Hyaluronic acid; PRO-C3: N-terminal type III collagen propeptide; PIIINP: Amino-terminal propeptide of type III procollagen. Serological biomarkers are listed in the order they appear in the text.

**Table 2 Serological biomarkers for the detection of nonalcoholic fatty liver disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Marker** | **Ref.** | **Country** | **Categories Tested** | **Sample size (*n*)** | **Dx** | **Cutoff** | **AUROC (95%CI)** | **Sens (%)** | **Spec (%)** | **PPV (%)** | **NPV (%)** | ***P* value** |
| **Adipo-nectin [µg/mL]** | Boyraz *et al*[24], 2013 | Turkey | NAFLD *vs* no-NAFLD | Obese with NAFLD (*n* = 63), obese non-NAFLD (*n* = 85) | US | 3.2 | 0.948 (0.924-0.972) | 100 | 83.5 |  |  | < 0.001 |
| **Adipo-nectin [µg/mL]** | Boyraz *et al*[24], 2013 | Turkey | Grade 3 *vs* Grade 1-2 steatosis | Obese with NAFLD (*n* = 63), obese non-NAFLD (*n* = 85) | US | 2.56 | 0.809 (0.751-0.867) | 84.2 | 63.6 |  |  | < 0.001 |
| **Adipo-nectin [µg/mL]** | Mohamed *et al*[25], 2017 | Egypt | NAFLD *vs* no-NAFLD | NAFLD (*n* = 101), non-NAFLD controls (*n* = 57) | Biopsy | 2.4 | 0.9213 | 74.3 | 96.5 |  |  | < 0.001 |
| **ALT** | Flisiak-Jackiewicz *et al*[19], 2018 | Poland | NAFLD *vs* no-NAFLD | Obese with steatosis (*n* = 72), obese without steatosis (*n* = 20) | MRS |  | 0.668 (0.514-0.822) |  |  |  |  | 0.0325 |
| **AST** | Flisiak-Jackiewicz *et al*[19], 2018 | Poland | NAFLD *vs* no-NAFLD | Obese with steatosis (*n* = 72), obese without steatosis (*n* = 20) | MRS |  | 0.683 (0.532-0.834) |  |  |  |  | 0.0173 |
| **Cheme-rin [ng/mL]** | Mohamed *et al*[25], 2017 | Egypt | NAFLD *vs* no-NAFLD | NAFLD (*n* = 101), non-NAFLD controls (*n* = 57) | Biopsy | 186.7 | 0.7836 | 56.4 | 87.7 | 88.9 | 52.6 | < 0.001 |
| **Cheme-rin [ng/mL]** | Kłusek-Oksiuta *et al*[46], 2014 | Poland | NAFLD *vs* no-NAFLD | Steatosis (*n* = 33 *via* MRS) | MRS | 190 | 0.7 | 75.0 | 58.0 |  |  | 0.04 |
| **FGF-21 [pg/mL]** | Hua *et al*[38], 2019 | Taiwan | Predicting high grade steatosis | Obese (*n* = 31), obese with liver steatosis (*n* = 83), controls (*n* = 89) | US | 106.1 | 0.781 (0.687–0.874) | 86.5 | 60.0 |  |  | < 0.001 |
| **FGF-21 + GGT** | Hua *et al*[38], 2019 | Taiwan | Predicting high grade steatosis | Obese (*n* = 31), obese with liver steatosis (*n* = 83), controls (*n* = 89) | US | 3.318 | 0.861 (0.786–0.937) | 89.2 | 74.6 |  |  | < 0.001 |
| **FGF-21 + GGT + TG** | Hua *et al*[38], 2019 | Taiwan | Predicting high grade steatosis | Obese (*n* = 31), obese with liver steatosis (*n* = 83), controls (*n* = 89) | US | 5.403 | 0.871 (0.801–0.942) | 83.8 | 82.5 |  |  | < 0.001 |
| **FGF-21 + GGT + TG** | Hua *et al*[38], 2019 | Taiwan | Predicting high grade steatosis | Obese (*n* = 31), obese with liver steatosis (*n* = 83), controls (*n* = 89) | US | 6.661 | 0.873 (0.801–0.945) | 94.6 | 72.9 |  |  | < 0.001 |
| **GGT** | Flisiak-Jackiewicz *et al*[19], 2018 | Poland | NAFLD vs. no-NAFLD | Obese with steatosis (*n* = 72), obese without steatosis (*n* = 20) | MRS |  | 0.677 (0.521-0.832) |  |  |  |  | 0.0257 |
| **GGT [U/L]** | Hua *et al*[38], 2019 | Taiwan | Predicting high grade steatosis | Obese (*n* = 31), obese with liver steatosis (*n* = 83), controls (*n* = 89) | US | 21.5 | 0.840 (0.765–0.915) | 82.5 | 70.5 |  |  | < 0.001 |
| **IL-17 [pg/mL]** | Duan *et al*[18], 2022 | China | Obese with NAFLD *vs* obese | Obese with NAFLD (*n* = 176), obese non-NAFLD (*n* = 91) | US | 40.03 | 0.97 (0.96-0.99) | 89.0 | 93.8 |  |  | < 0.001 |
| **IL-18 [pg/mL]** | Flisiak-Jackiewicz *et al*[19], 2018 | Poland | NAFLD *vs* no-NAFLD | Obese with steatosis (*n* = 72), obese without steatosis (*n* = 20) | MRS | 326.8 | 0.680 (0.552-0.808) | 60.0 | 75.0 | 34.0 | 60.0 | 0.0058 |
| **IL18 + ALT + AST + GGT + TG** | Flisiak-Jackiewicz *et al*[19], 2018 | Poland | NAFLD *vs* no-NAFLD | Obese with steatosis (*n* = 72), obese without steatosis (*n* = 20) | MRS |  | 0.782 (0.678-0.887) | 61.0 | 85.0 | 94.0 | 38.0 | < 0.001 |
| **IL-1β [pg/mL]** | Duan *et al*[18], 2022 | China | Obese with NAFLD *vs* obese | Obese with NAFLD (*n* = 176), obese non-NAFLD (*n* = 91) | US | 11.74 | 0.94 (0.91-0.97) | 84.6 | 85.2 |  |  | < 0.001 |
| **IL-6 [pg/mL]** | Duan *et al*[18], 2022 | China | Obese with NAFLD *vs* obese | Obese with NAFLD (*n* = 176), obese non-NAFLD (*n* = 91) | US | 8.1 | 0.94 (0.91-0.96) | 91.2 | 80.1 |  |  | < 0.001 |
| **RBP4 [µg/mL]** | Boyraz *et al*[24], 2013 | Turkey | NAFLD *vs* no-NAFLD | Obese with NAFLD (*n* = 63), obese non-NAFLD (*n* = 85) | US | 26 | 0.974 (0.960-0.988) | 100 | 92.9 |  |  | < 0.001 |
| **RBP4 [µg/mL]** | Boyraz *et al*[24], 2013 | Turkey | Grade 3 *vs* Grade 1-2 steatosis | Obese with NAFLD (*n* = 63), obese non-NAFLD (*n* = 85) | US | 35 | 0.782 (0.726-0.838) | 84.2 | 68.2 |  |  | < 0.001 |
| **Resistin [ng/mL]** | Boyraz *et al*[24], 2013 | Turkey | NAFLD *vs* no-NAFLD | Obese with NAFLD (*n* = 63), obese non-NAFLD (*n* = 85) | US | 12 | 0.884 (0.849-0.919) | 100 | 77.7 |  |  | < 0.001 |
| **Resistin [ng/mL]** | Boyraz *et al*[24], 2013 | Turkey | Grade 3 *vs* Grade 1-2 steatosis | Obese with NAFLD (*n* = 63), obese non-NAFLD (*n* = 85) | US | 5.2 | 0.661 (0.586-0.736) | 36.8 | 95.5 |  |  | < 0.05 |
| **TG** | Flisiak-Jackiewicz *et al*[19], 2018 | Poland | NAFLD *vs* no-NAFLD | Obese with steatosis (*n* = 72), obese without steatosis (*n* = 20) | MRS |  | 0.694 (0.574-0.815) |  |  |  |  | 0.0015 |
| **TG [mg/dL]** | Hua *et al*[38], 2019 | Taiwan | Predicting high grade steatosis | Obese (*n* = 31), obese with liver steatosis (*n* = 83), controls (*n* = 89) | US | 77 | 0.732 (0.639–0.824) | 90.2 | 50.0 |  |  | < 0.001 |
| **Visfatin [ng/mL]** | Elkabany *et al*[47], 2020 | Egypt | NAFLD *vs* no-NAFLD | Obese with NAFLD (*n* = 31), obese (*n* = 49), nonobese controls (*n* = 40) | US | 18 |  | 83.9 | 81.4 |  |  |  |

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AUROC: Area under the receiving operating characteristic; CI: Confidence interval; Dx: Diagnosis; IL, Interleukin; FGF: Fibroblast growth factor; GGT: Gamma-glutamyl transferase; MRS: Magnetic spectroscopy; NAFLD: Nonalcoholic fatty liver disease; NPV: Negative predictive value; PPV: Positive predictive value; RBP4: Retinol binding protein 4; Sens: Sensitivity; Spec: Specificity; TG: Triglycerides; US: Ultrasound.

**Table 3 Serological biomarkers and composite scores for the detection of nonalcoholic steatohepatitis**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Marker** | **Ref.** | **Country** | **Categories Tested** | **Sample size (*n*)** | **Dx** | **Cutoff** | **AUROC (95%CI)** | **Sens (%)** | **Spec (%)** | **PPV (%)** | **NPV (%)** | ***P* value** |
| **ALT** | Feldstein *et al*[66], 2013 | Italy | Diagnosing NASH | NASH (*n* = 140), non-NASH (*n* = 61) | Biopsy |  | 0.635 (0.556, 0.715) |  |  |  |  | < 0.001 |
| **ALT** | Walen-bergh *et al*[70], 2015 | Italy | Borderline NASH *vs* definite NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy |  | 0.57 |  |  |  |  | 0.0011 (CatD *vs* ALT) |
| **ALT** | Walen-bergh *et al*[70], 2015 | Italy | Steatosis + Borderline NASH *vs* NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (n = 96) | Biopsy |  | 0.53 |  |  |  |  | < 0.001 (CatD *vs* ALT) |
| **ALT** | Walen-bergh *et al*[70], 2015 | Italy | Steatosis *vs* borderline NASH + NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy |  | 0.66 |  |  |  |  | 0.103 (CatD *vs* ALT) |
| **ALT [U/L]** | Walen-bergh *et al*[70], 2015 | Italy | Steatosis *vs* NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy | > 64.5 | 0.59 | 61.5 | 68.4 | 72.7 | 56.5 | 0.0004 (CatD *vs* ALT) |
| **Ang-2 [ng/mL]** | Manco *et al*[57], 2022 | Italy | Diagnosing NASH | NAFLD (*n* = 76), controls (*n* = 28, by ultrasound) | Biopsy | 135.4 | 0.911 (0.844–0.979) | 85.7 | 85.3 | 83.0 | 87.5 | < 0.001 |
| **AST** | Feldstein *et al*[66], 2013 | Italy | Diagnosing NASH | NASH (*n* = 140), non-NASH (*n* = 61) | Biopsy |  | 0.651 (0.573, 0.728) |  |  |  |  | < 0.001 |
| **CatD** | Walen-bergh *et al*[70], 2015 | Italy | Borderline NASH *vs* definite NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy |  | 0.85 |  |  |  |  |  |
| **CatD** | Walen-bergh *et al*[70], 2015 | Italy | Steatosis + Borderline NASH *vs* NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy |  | 0.88 |  |  |  |  |  |
| **CatD** | Walen-bergh *et al*[70], 2015 | Italy | Steatosis *vs* borderline NASH + NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy |  | 0.81 |  |  |  |  |  |
| **CatD [pg/mL]** | Walen-bergh *et al*[70], 2015 | Italy | Steatosis *vs* NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy | < 18445 | 0.94 | 100 | 89.5 | 92.9 | 100.0 |  |
| **Change in ALT** | Vuppa-lanchi *et al*[68], 2014 | United States | Overall his-tologic im-provement | NAFLD (*n* = 117) | Biopsy |  | 0.79 (0.70-0.87) |  |  |  |  |  |
| **Change in ALT** | Vuppa-lanchi *et al*[68], 2014 | United States | Resolution of NASH | NAFLD (*n* = 117) | Biopsy |  | 0.84 (0.76-0.93) |  |  |  |  |  |
| **Change in ALT + CK18** | Vuppa-lanchi *et al*[68], 2014 | United States | Overall his-tologic im-provement | NAFLD (*n* = 117) | Biopsy |  | 0.79 (0.71-0.87) |  |  |  |  | 0.08 (CK18+ALT *vs* ALT) |
| **Change in ALT + CK18** | Vuppa-lanchi *et al*[68], 2014 | United States | Resolution of NASH | NAFLD (*n* = 117) | Biopsy |  | 0.83 (0.75-0.92) |  |  |  |  | 0.92 (CK18+ALT *vs* ALT) |
| **Change in CK18** | Vuppa-lanchi *et al*[68], 2014 | United States  | Overall his-tologic im-provement | NAFLD (*n* = 117) | Biopsy |  | 0.72 (0.63-0.81) |  |  |  |  | 0.42 (CK18 *vs* ALT) |
| **Change in CK18** | Vuppa-lanchi *et al*[68], 2014 | United States | Resolution of NASH | NAFLD (*n* = 117) | Biopsy |  | 0.69 (0.58-0.79) |  |  |  |  | 0.005 (CK18 *vs* ALT) |
| **CK18** | Walen-bergh *et al*[70], 2015 | Italy | Borderline NASH *vs* definite NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy |  | 0.57 |  |  |  |  | 0.0003 (CatD *vs* CK18) |
| **CK18** | Walen-bergh *et al*[70], 2015 | Italy | Steatosis + Borderline NASH *vs* NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy |  | 0.52 |  |  |  |  | < 0.0001 (CatD *vs* CK18) |
| **CK18** | Walen-bergh *et al*[70], 2015 | Italy | Steatosis *vs* borderline NASH + NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy |  | 0.74 |  |  |  |  | 0.4299 (CatD *vs* CK18) |
| **CK18 [U/L]** | Manco *et al*[57], 2022 | Italy | Diagnosing NASH | NAFLD (*n* = 76), controls (*n* = 28, by ultrasound) | Biopsy | 352 | 0.827 (0.735–0.919) | 77.1 | 73.2 | 71.0 | 78.9 | < 0.001 |
| **CK18 [U/L]** | Fitz-patrick *et al*[67], 2010 | United King-dom | Predicting NASH | NAFLD (*n* = 45), controls (*n* = 13) | Biopsy | 207 | 0.85 (0.73–0.96) | 84.0 | 88.0 | 90.0 | 80.0 |  |
| **CK18 [U/L]** | Feldstein *et al*[66], 2013 | Italy | Diagnosing NASH | NASH (*n* = 140), non-NASH (*n* = 61) | Biopsy | 233 | 0.9334 | 85.0 | 86.9 | 93.7 | 71.6 | < 0.001 |
| **CK18 [U/L]** | Walen-bergh *et al*[70], 2015 | Italy | Steatosis *vs* NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy | > 327.5 | 0.72 | 72.0 | 63.2 | 72.8 | 62.2 | 0.0225 (CatD *vs* CK18) |
| **GGT** | Feldstein *et al*[66], 2013 | Italy | Diagnosing NASH | NASH (*n* = 140), non-NASH (*n* = 61) | Biopsy |  | 0.672 (0.594-0.750) |  |  |  |  | < 0.001 |
| **Leptin [ng/mL]** | Manco *et al*[95], 2007 | Italy | Predicting NAFLD Activity Score | NAFLD (*n* = 72), F0 (*n* = 31), F1 (*n* = 41) | Biopsy | ≤ 14.9 | 0.833 | 9.0 | 36.0 | 5.0 | 47.0 |  |
| **Leptin [ng/mL]** | Manco *et al*[95], 2007 | Italy | Predicting NAFLD Activity Score | NAFLD (*n* = 72), F0 (*n* = 31), F1 (*n* = 41) | Biopsy | ≥ 20.4 |  | 54.0 | 76.0 | 50.0 | 79.0 |  |
| **PIIINP [ng/mL]** | Mosca *et al*[101], 2019 | Italy | Definite NASH *vs* No/Borderline NASH | No/borderline NASH (*n* = 115), definite NASH (*n* = 89) | Biopsy | > 7.60 | 0.737 (0.66-0.81) | 62.0 | 91.0 | 85.0 | 75.0 |  |
| **TNF-α [pg/mL]** | Manco *et al*[95], 2007 | Italy | Predicting NAFLD Activity Score | NAFLD (*n* = 72), F0 (*n* = 31), F1 (*n* = 41) | Biopsy | ≤ 5.9 | 0.911 | 18.0 | 36.0 | 11.0 | 5.0 |  |
| **TNF-α [pg/mL]** | Manco *et al*[95], 2007 | Italy | Predicting NAFLD Activity Score | NAFLD (*n* = 72), F0 (*n* = 31), F1 (*n* = 41) | Biopsy | ≥ 7.9 |  | 82.0 | 96.0 | 90.0 | 96.0 |  |

AUROC: Area under the receiver operating characteristic curve; ALT: Alanine aminotransferase; Ang-2: Angiopoietin-2; AST: Aspartate aminotransferase; CatD: Cathepsin D; CK18: Cytokeratin 18; CI: Confidence interval; Dx: Diagnosis; GGT: Gamma-glutamyl transferase; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; NPV: Negative predictive value; PPV: Positive predictive value; Sens: Sensitivity; Spec: Specificity; TNF-a: Tumor necrosis factor alpha.

**Table 4 Serological biomarkers for the detection of fibrosis in nonalcoholic fatty liver disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Marker** | **Ref.** | **Country** | **Categories Tested** | **Sample size (*n*)** | **Dx** | **Cutoff** | **AUROC (95%CI)** | **Sens (%)** | **Spec (%)** | **PPV (%)** | **NPV (%)** | ***P* value** |
| **CK18** | Mandelia *et al*[84], 2016 | Italy | F1-F3 *vs* F0 | NAFLD (*n* = 201), F0 (*n* = 65), F1–F3 (*n* = 136) | Biopsy |  | 0.75 (0.68-0.81) |  |  |  |  |  |
| **CK18** | Mandelia *et al*[84], 2016 | Italy | F2-F2 *vs* F0 | NAFLD (*n* = 201), F0 (*n* = 65), F1–F3 (*n* = 136) | Biopsy |  | 0.67 (0.54-0.80) |  |  |  |  |  |
| **CK18** | Mandelia *et al*[84], 2016 | Italy | F3 *vs* F0 | NAFLD (*n* = 201), F0 (*n* = 65), F1–F3 (*n* = 136) | Biopsy |  | 0.77 (0.56-0.97) |  |  |  |  |  |
| **CK18 [U/L]** | Fitz-patrick *et al*[67], 2010 | United King-dom | Significant Fibrosis (≥ F2) | NAFLD (*n* = 45), healthy controls (*n* = 13) | Biopsy | 200 | 0.66 (0.5-0.82) | 83.0 | 40.0 |  |  |  |
| **CK18 [U/L]** | Leben-sztejn *et al*[80], 2011 | Poland | Fibrosis (F1-F3) *vs* F0 | NAFLD (*n* = 52), NAFLD with obesity/overweight (*n* = 42), healthy non-obese controls (*n* = 25) | Biopsy | 210 | 0.666 | 79.0 | 60.0 | 56.0 | 82.0 | 0.05 |
| **HA [ng/mL]** | Nobili *et al*[79], 2010 | Italy | F1 and F2+ *vs* F0 | NAFLD (*n* = 100), F0 (*n* = 35), ≥ F1 (*n* = 65) | Biopsy | ≥ 1200 | 0.88 (0.81–0.96) |  |  | 90.0 | 50.0 |  |
| **HA [ng/mL]** | Nobili *et al*[79], 2010 | Italy | F2+ *vs* F0 and F1 | NAFLD (*n* = 100), F0 (*n* = 35), ≥ F1 (*n* = 65) | Biopsy | 2100 | 0.95 (0.91–0.99) |  |  | 40.0 | 90.0 |  |
| **HA [ng/mL]** | Leben-sztejn *et al*[80], 2011 | Poland | Fibrosis (F1-F3) *vs* F0 | NAFLD (*n* = 52), NAFLD with obesity/overweight (*n* = 42), healthy non-obese controls (*n* = 25) | Biopsy | 19.1 | 0.672 | 84.0 | 55.0 | 52.0 | 86.0 | 0.04 |
| **HA + CK18** | Leben-sztejn *et al*[80], 2011 | Poland | Fibrosis (F1-F3) *vs* F0 | NAFLD (*n* = 52), NAFLD with obesity/overweight (*n* = 42), healthy non-obese controls (*n* = 25) | Biopsy |  | 0.73 | 74.0 | 79.0 | 56.0 | 63.0 | 0.002 |
| **PIIINP [ng/mL]** | Hamza *et al*[99], 2016 | Egypt | Presence of steatosis in obese children | Obese with NAFLD (*n* = 50), obese without NAFLD (*n* = 5), nonobese healthy controls (*n* = 30) | US | 8.5 |  | 74.0 | 33.0 |  |  |  |
| **PIIINP [ng/mL]** | Mosca *et al*[101], 2019 | Italy | Presence of ≥ F2 | No/borderline NASH (*n* = 115), definite NASH (*n* = 89) | Biopsy | > 8.89 | 0.921 (0.87-0.97) | 84.0 | 94.0 | 95.0 | 79.0 |  |
| **PIIINP [ng/mL]** | Mosca *et al*[101], 2019 | Italy | Presence of F3 | No/borderline NASH (*n* = 115), definite NASH (*n* = 89) | Biopsy | > 13.2 | 0.993 (0.98-1.0) | 100 | 98.0 | 78.0 | 100 |  |

AUROC: Area under the receiver operating characteristic curve; CK18: Cytokeratin 18; CI: Confidence interval; Dx: Diagnosis; F: Fibrosis stage; HA: Hyaluronic acid; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; NPV: Negative predictive value; PIIINP: Amino-terminal propeptide of type III procollagen; PPV: Positive predictive value; Sens: Sensitivity; Spec: Specificity; US: Ultrasound.

**Table 5 Imaging biomarkers for the detection of nonalcoholic fatty liver disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Marker** | **Ref.** | **Country** | **Categories Tested** | **Sample size (*n*)** | **Dx** | **Cutoff** | **AUROC (95%CI)** | **Sens (%)** | **Spec (%)** | **PPV (%)** | **NPV (%)** | ***P* value** |
| **CAP [dB/m]** | Yang *et al*[106], 2022 | China | Predicting NAFL in with obesity | NAFLD (*n* = 61), Non-NAFLD (*n* = 59), NAFL (*n* = 44), NASH (*n* = 17) | US | > 262.5 | 0.659 (0.561-0.758) | 59.1 | 60.5 |  |  | 0.0037 |
| **CAP [dB/m]** | Yang *et al*[106], 2022 | China | Predicting NAFL in with obesity | NAFLD (*n* = 61), Non-NAFLD (*n* = 59), NAFL (*n* = 44), NASH (*n* = 17) | US | > 258 | 0.757 (0.668-0.845) | 67.2 | 67.2 |  |  | <0.001 |
| **CAP [dB/m]** | Chaidez *et al*[105], 2022 | United States | S1-S3 *vs* S0 | Total (*n* = 206), NAFLD (*n* = 116), Non-NAFLD (*n* = 90) | Biopsy | ≥ 259  | 0.98 (0.96-0.99) | 94.0 | 91.0 | 97.0 | 91.0 |  |
| **LSM [kPa]** | Yang *et al*[106], 2022 | China | Predicting NAFL in with obesity | NAFLD (*n* = 61), Non-NAFLD (*n* = 59), NAFL (*n* = 44), NASH (*n* = 17) | US | > 4.95 | 0.674 (0.577-0.771) | 61.4 | 64.5 |  |  | 0.0015 |
| **LSM [kPa]** | Yang *et al*[106], 2022 | China | Predicting NAFL in with obesity | NAFLD (*n* = 61), Non-NAFLD (*n* = 59), NAFL (*n* = 44), NASH (*n* = 17) | US | > 4.65 | 0.768 (0.684-0.852) | 70.5 | 70.7 |  |  | < 0.001 |
| **MRE [kPa]** | Trout *et al*[134], 2018 | United States | NAFLD stage 0-1 *vs* ≥ stage 2 fibrosis in patients with steatosis | Total (*n* = 86), Ludwig ≥ stage 2 (*n* = 51), steatosis (*n* = 44) | Biopsy | 2.28 | 0.53 (0.35-0.71) | 52.2 | 71.4 |  |  |  |
| **MRE [kPa]** | Trout *et al*[134], 2018 | United States | NAFLD stage 0-1 *vs* ≥ stage 2 fibrosis in patients with steatosis | Total (*n* = 86), Ludwig ≥ stage 2 (*n* = 51), steatosis (*n* = 44) | Biopsy | 0.94 |  | 13.0 | 100 |  |  |  |
| **MRI-PDFF [%]** | Middle-ton *et al*[121], 2018 | United States | Grade 1 steatosis *vs* grade 2-3 | Baseline MRI (*n* = 110), no baseline MRI (*n* = 59) | Biopsy | 17.5 | 0.87 (0.80-0.94) | 74.0 | 90.0 | 97.0 | 41.0 |  |
| **MRI-PDFF [%]** | Middle-ton *et al*[121], 2018 | United States | Grade 1-2 steatosis *vs* grade 3 | Baseline MRI (*n* = 110), no baseline MRI (*n* = 59) | Biopsy | 23.3 | 0.79 (0.70-0.87) | 60.0 | 90.0 | 88.0 | 65.0 |  |
| **MRI-PDFF [%]** | Middle-ton *et al*[121], 2018 | United States | Decrease in steatosis grade | Baseline MRI (*n* = 110), no baseline MRI (*n* = 59) | Biopsy | -11 | 0.76 (0.66-0.87) | 31.0 | 90.0 | 78.0 | 60.0 |  |
| **MRI-PDFF [%]** | Middle-ton *et al*[121], 2018 | United States | Increase in steatosis grade | Baseline MRI (*n* = 110), no baseline MRI (*n* = 59) | Biopsy | 5.5 | 0.83 (0.73-0.92) | 40.0 | 90.0 | 33.0 | 92.0 |  |
| **MRI-PDFF [%]** | Zhao *et al*[123], 2019 | China | Detecting ≥ S1 | Total (*n* = 86), Obese/overweight (*n* = 65), healthy nonobese controls (*n* = 21) | MRS | 5.1 | 0.991 (0.977-1.00) | 95.0 | 100 |  |  |  |
| **MRI-PDFF [%]** | Di Martino *et al*[122], 2016 | United States | Presence of steatosis | NASH (*n* = 27), healthy controls (*n* = 27) | Biopsy | 3.5 |  | 89.0 | 88.0 |  |  |  |
| **MRS [%]** | Di Martino *et al*[122], 2016 | United States | Presence of steatosis | NASH (*n* = 27), healthy controls (*n* = 27) | Biopsy | 6 |  | 92.6 | 95.7 |  |  |  |

AUROC: Area under the receiving operating characteristic; CAP: Controlled attenuation parameter; CI: Confidence interval; Dx: Diagnosis; LSM: Liver stiffness measurement; MRE: Magnetic resonance elastography; MRI: Magnetic resonance imaging; MRS: Magnetic spectroscopy; NAFL: Nonalcoholic fatty liver; NAFLD: Nonalcoholic fatty liver disease; NPV: Negative predictive value; PDFF: Proton density fat fraction; PPV: Positive predictive value; Sens: Sensitivity; Spec: Specificity; US: Ultrasound.

**Table 6 Imaging biomarkers for the detection of nonalcoholic steatohepatitis and the detection of fibrosis in nonalcoholic fatty liver disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Marker** | **Ref.** | **Country** | **Categories Tested** | **Sample size (*n*)** | **Dx** | **Cutoff** | **AUROC (95%CI)** | **Sens (%)** | **Spec (%)** | **PPV (%)** | **NPV (%)** | ***P* value** |
| **CAP [dB/m]** | Yang *et al*[106], 2022 | China | Predicting NASH in children with obesity | NAFLD (*n* = 61), Non-NAFLD (*n* = 59), NAFL (*n* = 44), NASH (*n* = 17) | US | > 276 | 0.722 (0.602-0.843) | 70.6 | 72.8 |  |  | 0.0058 |
| **LSM** | Chaidez *et al*[105], 2022 | United States | F0-F2 *vs* F3-F6 (Ishak) | Total (*n* = 206) | Biopsy |  | 0.73 (0.64-0.81) |  |  |  |  |  |
| **LSM** | Chaidez *et al*[105], 2022 | United States | F0-F2 *vs* F3-F6 (Ishak) | NAFLD (*n* = 116) | Biopsy |  | 0.77 (0.67-0.88) |  |  |  |  |  |
| **LSM** | Chaidez *et al*[105], 2022 | United States | F0-F2 *vs* F3-F6 (Ishak) | Non-NAFLD (*n* = 90) | Biopsy |  | 0.70 (0.56-0.83) |  |  |  |  |  |
| **LSM [kPa]** | Yang *et al*[106], 2022 | China | Predicting NASH in children with obesity | NAFLD (*n* = 61), Non-NAFLD (*n* = 59), NAFL (*n* = 44), NASH (*n* = 17) | US | > 5.15 | 0.725 (0.611-0.839) | 64.7 | 65.0 |  |  | 0.0048 |
| **MRE [kPa]** | Xantha-kos *et al*[132], 2014 | United States | F2-F4 *vs* F0-F1 | Chronic liver disease (*n* = 35; 27 with NAFLD); F0-F1 (*n* = 27), F2-F4 (*n* = 8) | Biopsy | 2.71 | 0.92 (0.79-1.00) | 88.0 | 85.0 |  |  | 0.02 |
| **MRE [kPa]** | Schwim-mer *et al*[133], 2017 | United States | Any Fibrosis (F0 *vs* F1-4) | F0 (*n* = 54), F1 (*n* = 24), F2 (*n* = 6), F3 (*n* = 5), F4 (*n* = 1) | Biopsy | ≥ 2.77 | 0.77 | 44.4 | 90.7 | 76.2 | 71.0 |  |
| **MRE [kPa]** | Schwim-mer *et al*[133], 2017 | United States | Any Fibrosis (F0 *vs* F1-4) | F0 (*n* = 54), F1 (*n* = 24), F2 (*n* = 6), F3 (*n* = 5), F4 (*n* = 1) | Biopsy | ≥ 2.69 | 0.79 | 47.2 | 88.9 | 73.9 | 71.6 |  |
| **MRE [kPa]** | Schwim-mer *et al*[133], 2017 | United States | Any Fibrosis (F0 *vs* F1-4) | F0 (*n* = 54), F1 (*n* = 24), F2 (*n* = 6), F3 (*n* = 5), F4 (*n* = 1) | Biopsy | ≥ 2.78 | 0.772 | 44.4 | 90.7 | 76.2 | 71.0 |  |
| **MRE [kPa]** | Schwim-mer *et al*[133], 2017 | United States | Advanced Fibrosis (F0-2 *vs* F3-4) | F0 (*n* = 54), F1 (*n* = 24), F2 (*n* = 6), F3 (*n* = 5), F4 (*n* = 1) | Biopsy | ≥ 3.05 | 0.925 (0.539-0.989) | 50.0 | 91.7 | 30.0 | 96.2 |  |
| **MRE [kPa]** | Schwim-mer *et al*[133], 2017 | United States | Advanced Fibrosis (F0-2 *vs* F3-4) | F0 (*n* = 54), F1 (n = 24), F2 (*n* = 6), F3 (*n* = 5), F4 (*n* = 1) | Biopsy | ≥ 3.03 | 0.879 (0.539-0.898) | 33.3 | 94.0 | 28.6 | 95.2 |  |
| **MRE [kPa]** | Schwim-mer *et al*[133], 2017 | United States | Advanced Fibrosis (F0-2 *vs* F3-4) | F0 (*n* = 54), F1 (*n* = 24), F2 (*n* = 6), F3 (*n* = 5), F4 (*n* = 1) | Biopsy | ≥ 3.33 | 0.894 (0.682-0.959) | 33.3 | 90.5 | 20.0 | 95.0 |  |
| **MRE [kPa]** | Trout *et al*[134], 2018 | United States | Ludwig stage 0-1 *vs* ≥ stage 2 fibrosis in total cohort | Total (*n* = 86; 48 with NAFLD), Ludwig ≥ stage 2 (*n* = 51), steatosis (*n* = 44) | Biopsy | 2.27 | 0.70 (0.59-0.81) | 68.6 | 74.3 |  |  |  |
| **MRE [kPa]** | Trout *et al*[134], 2018 | United States | Ludwig stage 0-1 *vs* ≥ stage 2 fibrosis in total cohort | Total (*n* = 86; 48 with NAFLD), Ludwig ≥ stage 2 (*n* = 51), steatosis (*n* = 44) | Biopsy | 1.67 |  | 35.3 | 91.4 |  |  |  |
| **MRE [kPa]** | Trout *et al*[134], 2018 | United States | Ludwig stage 0-2 from ≥ stage 3 fibrosis | Total (*n* = 86; 48 with NAFLD), Ludwig ≥ stage 2 (*n* = 51), steatosis (*n* = 44) | Biopsy | 6.55 | 0.90 (0.83-0.97) | 85.7 | 77.8 |  |  |  |
| **MRE [kPa]** | Trout *et al*[134], 2018 | United States | Ludwig stage 0-2 from ≥ stage 3 fibrosis | Total (*n* = 86; 48 with NAFLD), Ludwig ≥ stage 2 (*n* = 51), steatosis (*n* = 44) | Biopsy | 5.41 |  | 64.3 | 93.1 |  |  |  |
| **MRE [kPa]** | Trout *et al*[134], 2018 | United States | Ludwig stage 0-1 *vs* ≥ stage 2 fibrosis in patients with steatosis (*n* = 41) | Total (*n* = 86; 48 with NAFLD), Ludwig ≥ stage 2 (*n* = 51), steatosis (*n* = 44) | Biopsy |  | 0.53 (0.35-0.71) |  |  |  |  |  |
| **MRE [kPa]** | Trout *et al*[134], 2018 | United States | Ludwig stage 0-1 *vs* ≥ stage 2 fibrosis in patients without steatosis (*n* = 45) | Total (*n* = 86; 48 with NAFLD), Ludwig ≥ stage 2 (*n* = 51), steatosis (*n* = 44) | Biopsy |  | 0.82 (0.67-0.96) |  |  |  |  |  |
| **PNFI** | Alkhouri *et al*[108], 2012 | Italy | ≥ F2 | F0-F1 (*n* = 57), F2-F3 (*n* = 10) | Biopsy | 8.2 | 0.747 (0.632-0.820) |  |  |  |  | 0.005 |
| **TE [kPa]** | Nobili *et al*[107], 2008 | Italy | ≥ F1 | F0 (*n* = 11), F1 (*n* = 27), F2 (*n* = 7), F3-4 (*n* = 5) | Biopsy | 5.1 | 0.97 (0.90-0.99) | 97.0 | 91.0 | 97.0 | 91.0 |  |
| **TE [kPa]** | Nobili *et al*[107], 2008 | Italy | ≥ F2 | F0 (*n* = 11), F1 (*n* = 27), F2 (*n* = 7), F3-4 (*n* = 5) | Biopsy | 7.4 | 0.99 (0.92-0.99) | 100 | 92.0 | 80.0 | 100 |  |
| **TE [kPa]** | Nobili *et al*[107], 2008 | Italy | ≥ F3 | F0 (*n* = 11), F1 (*n* = 27), F2 (*n* = 7), F3-4 (*n* = 5) | Biopsy | 10.2 | 1.00 (0.94-1.00) | 100 | 100 | 100 | 100 |  |
| **TE [kPa]** | Alkhouri *et al*[108], 2012 | Italy | ≥ F2 | F0-F1 (*n* = 57), F2-F3 (*n* = 10) | Biopsy | 8.6 | 1.00 (0.981-1.00) |  |  |  |  |  |

AUROC: Area under the receiving operating characteristic; CAP: Controlled attenuation parameter; CI: Confidence interval; DX: Diagnosis; F: Fibrosis stage; LSM: Liver stiffness measurement; MRE: Magnetic resonance elastography; NAFL: Nonalcoholic fatty liver; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; NPV: Negative predictive value; PNFI: Proton density fat fraction index; PPV: Positive predictive value; Sens: Sensitivity; Spec: Specificity; TE: Transient elastography.

**Table 7 Composite scores for the detection of nonalcoholic steatohepatitis**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Scores** | **Ref.** | **Country** | **Categories Tested** | **Sample size (*n*)** | **Dx** | **Cutoff** | **AUROC (95%CI)** | **Sens (%)** | **Spec (%)** | **PPV (%)** | **NPV (%)** |
| **Ang-2 + CK18** | Manco *et al*[57], 2022 | Italy | Diagnosing NASH | NAFLD (*n* = 76), healthy controls (*n* = 28, by ultrasound) | Biopsy |  |  | 71.4 | 100 | 100 | 80.4 |
| **APRI** | Mosca *et al*[101], 2019 | Italy | Definite NASH *vs* No/Borderline NASH | No/borderline NASH (*n* = 115), definite NASH (*n* = 89) | Biopsy | > 0.24 | 0.6826 | 58.0 | 72.0 | 69.0 | 62.0 |
| **CatD + CK18** | Walen-bergh *et al*[70], 2015 | Italy | Steatosis from NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy |  | 0.998 |  |  |  |  |
| **CatD + CK18** | Walen-bergh *et al*[70], 2015 | Italy | Borderline NASH *vs* definite NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy |  | 0.858 |  |  |  |  |
| **CatD + CK18** | Walen-bergh *et al*[70], 2015 | Italy | Steatosis + Borderline NASH *vs* NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy |  | 0.892 |  |  |  |  |
| **CatD + CK18** | Walen-bergh *et al*[70], 2015 | Italy | Steatosis *vs* borderline NASH + NASH | NASH (*n* = 26), borderline NASH (*n* = 51), steatosis (*n* = 19), obese (*n* = 96) | Biopsy |  | 0.85 |  |  |  |  |
| **FIB-4** | Mosca *et al*[101], 2019 | Italy | Definite NASH *vs* No/Borderline NASH | No/borderline NASH (*n* = 115), definite NASH (*n* = 89) | Biopsy | > 0.22 | 0.6369 | 48.0 | 73.0 | 65.0 | 58.0 |
| **Mean ALT over 96 wk** | Arsik *et al*[54], 2018 | United States | NASH | Fibrosis (*n* = 128), NASH (*n* = 131) | Biopsy |  | 81.84 | 80.5 | 83.0 |  |  |
| **Mean ALT over 96 wk** | Arsik *et al*[54], 2018 | United States | NASH + Fibrosis | Fibrosis (*n* = 128), NASH (*n* = 131) | Biopsy |  | 77.78 | 71.8 | 80.8 |  |  |
| **P1NP/ALP ratio** | Kwon *et al*[137], 2022 | Korea | Presence of steatohepa-titis | NAFLD (*n* = 60) | US | 1.46 | 0.788 (0.658-0.918) | 78.8 | 81.3 |  |  |
| **P1NP/ALP ratio × ALT** | Kwon *et al*[137], 2022 | Korea | Presence of steatohepa-titis | NAFLD (*n* = 60) | US | 119.08 | 0.894 (0.812-0.977) | 82.6 | 92.9 |  |  |
| **P1NP/osteocal-cin ratio** | Kwon *et al*[137], 2022 | Korea | Presence of steatohepa-titis | NAFLD (*n* = 60) | US | 3.54 | 0.782 (0.647-0.918) | 80.9 | 76.9 |  |  |
| **P1NP/Osteocal-cin ratio × ALT** | Kwon *et al*[137], 2022 | Korea | Presence of steatohepa-titis | NAFLD (*n* = 60) | US | 305.38 | 0.939 (0.88-0.999) | 83.0 | 92.3 |  |  |
| **Risk Score** | Manco *et al*[95], 2007 | Italy | Predicting NAFLD Activity Score | NAFLD (*n* = 72), F0 (*n* = 31), F1 (*n* = 41) | Biopsy | ≤ 12.9 | 0.985 | 9.0 | 2.0 | 4.0 | 33.0 |
| **Risk Score** | Manco *et al*[95], 2007 | Italy | Predicting NAFLD Activity Score | NAFLD (*n* = 72), F0 (*n* = 31), F1 (*n* = 41) | Biopsy | ≥ 13.5 |  | 81.0 | 92.0 | 82.0 | 92.0 |

ALP: Alkaline phosphatase; ALT: Alanine transaminase; Ang-2: Angiopoietin-2; APRI: AST to platelet ratio index; AUROC: Area under the receiving operating characteristic; CatD: Cathepsin D; CK18: Cytokeratin 18; CI: Confidence interval; Dx: Diagnosis; F: Fibrosis stage; FIB-4: Fibrosis-4; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; P1NP: Procollagen type 1 amino-terminal propeptide; PPV: Positive predictive value; NPV: Negative predictive value; Risk Score: 0.440 + (1.454 × ln leptin) + (4.617 × ln TNF-α); Sens: Sensitivity; Spec: Specificity; TNF-α: Tumor necrosis factor-alpha; US: Ultrasound.

**Table 8 Composite scores for the detection of fibrosis in nonalcoholic fatty liver disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Scores** | **Ref.** | **Country** | **Categories Tested** | **Sample size (*n*)** | **Dx** | **Cutoff** | **AUROC (95%CI)** | **Sens (%)** | **Spec (%)** | **PPV (%)** | **NPV (%)** | ***P* value** |
| **APRI** | Mosca *et al*[101], 2019 | Italy | Presence of ≥ F2 | No/borderline NASH (*n* = 115), definite NASH (*n* = 89) | Biopsy | > 0.24 | 0.7659 | 80 | 70 | 92 | 43 |  |
| **APRI** | Mosca *et al*[101], 2019 | Italy | Presence of F3 | No/borderline NASH (*n* = 115), definite NASH (*n* = 89) | Biopsy | > 0.26 | 0.8535 | 100 | 49 | 100 | 100 |  |
| **APRI** | Mosca *et al*[142], 2022 | Italy | > F1 | NAFLD (*n* = 286), F0 (n = 105), F1 (*n* = 140), F2 (*n* = 31), F3 (*n* = 2) | Biopsy |  | 0.619 |  |  | 62.8 | 52.0 |  |
| **APRI** | Mosca *et al*[142], 2022 | Italy | > F2 | NAFLD (*n* = 286), F0 (*n* = 105), F1 (*n* = 140), F2 (*n* = 31), F3 (*n* = 2) | Biopsy |  | 0.74 |  |  | 86 | 78.1 |  |
| **APRI** | Mansoor *et al*[140], 2015 | United States | Presence of F1-F4 | NAFLD (*n* = 92) | Biopsy |  | 0.800 (0.695-0.904) |  |  |  |  |  |
| **APRI** | Mansoor *et al*[140], 2015 | United States | Presence of F2-F4 | NAFLD (*n* = 92) | Biopsy |  | 0.666 (0.553-0.778) |  |  |  |  |  |
| **APRI** | Mansoor *et al*[140], 2015 | United States | Presence of F3-F4 | NAFLD (*n* = 92) | Biopsy |  | 0.628 (0.478-0.778) |  |  |  |  |  |
| **AST/ALT ratio** | Mansoor *et al*[140], 2015 | United States | Presence of F1-F4 | NAFLD (*n* = 92) | Biopsy |  | 0.572 (0.350, 0.793) |  |  |  |  |  |
| **AST/ALT ratio** | Mansoor *et al*[140], 2015 | United States | Presence of F2-F4 | NAFLD (*n* = 92) | Biopsy |  | 0.585 (0.466-0.703) |  |  |  |  |  |
| **AST/ALT ratio** | Mansoor *et al*[140], 2015 | United States | Presence of F3 - F4 | NAFLD (*n* = 92) | Biopsy |  | 0.441 (0.316-0.565) |  |  |  |  |  |
| **CK18 + WC per-centile** | Mandelia *et al*[84], 2016 | Italy | Presence of ≥ F1 | NAFLD (*n* = 201), F0 (*n* = 65), F1–F3 (*n* = 136) | Biopsy | ≥ 35 | 0.84 (0.79-0.90) | 97 | 38 | 76 | 86 |  |
| **CK18 + WC per-centile** | Mandelia *et al*[84], 2016 | Italy | Presence of ≥ F1 | NAFLD (*n* = 201), F0 (*n* = 65), F1–F3 (*n* = 136) | Biopsy | > 82 |  | 59 | 88 | 91 | 51 |  |
| **ELF** | Gawrieh *et al*[150], 2021 | United States | Any fibrosis (≥ F1) | NAFLD (*n* = 173), borderline/suspicious NASH (*n* = 73), definite NASH (*n* = 71) | Biopsy |  | 0.60 (0.50–0.70) |  |  |  |  | 0.11 |
| **ELF** | Gawrieh *et al*[150], 2021 | United States | Clinically significant (≥ F2) | NAFLD (*n* = 173), borderline/suspicious NASH (*n* = 73), definite NASH (*n* = 71) | Biopsy |  | 0.70 (0.60–0.80) |  |  |  |  | < 0.001 |
| **ELF** | Gawrieh *et al*[150], 2021 | United States | Advanced fibrosis (≥ F3) | NAFLD (*n* = 173), borderline/suspicious NASH (*n* = 73), definite NASH (*n* = 71) | Biopsy |  | 0.79 (0.69–0.89) |  |  |  |  | < 0.001 |
| **FAST score** | Chaidez *et al*[105], 2022 | United States | Significant liver disease (NAS ≥ 4 and Ishak ≥ 3) *vs* NAS < 4 / Ishak < 3) | Chronic liver disease (*n* = 206; 116 with NAFLD) | Biopsy | ≥ 0.67 | 0.75 (0.56-0.94) | 89 | 62 |  |  |  |
| **FIB-4** | Mosca *et al*[101], 2019 | Italy | Presence of ≥ F2 | No/borderline NASH (*n* = 115), definite NASH (*n* = 89) | Biopsy | > 0.22 | 0.7412 | 64 | 72 | 88 | 39 |  |
| **FIB-4** | Mosca *et al*[101], 2019 | Italy | Presence of F3 | No/borderline NASH (*n* = 115), definite NASH (*n* = 89) | Biopsy | > 0.24 | 0.7687 | 86 | 71 | 99 | 9 |  |
| **Mean ALT over 96 weeks** | Arsik *et al*[54], 2018 | United States | Fibrosis | Fibrosis (*n* = 128), NASH (*n* = 131) | Biopsy |  | 58.56 | 56.5 | 64.6 |  |  |  |
| **FIB-4** | Mosca *et al*[142], 2022 | Italy | > F1 | NAFLD (*n* = 286), F0 (*n* = 105), F1 (n = 140), F2 (*n* = 31), F3 (*n* = 2) | Biopsy |  | 0.545 |  |  | 62 | 52 |  |
| **FIB-4** | Mosca *et al*[142], 2022 | Italy | > F2 | NAFLD (*n* = 286), F0 (*n* = 105), F1 (*n* = 140), F2 (*n* = 31), F3 (*n* = 2) | Biopsy |  | 0.588 |  |  |  |  |  |
| **FIB-4** | Mansoor *et al*[140], 2015 | United States | Presence of F1-F4 | NAFLD (*n* = 92) | Biopsy |  | 0.547 (0.375-0.719) |  |  |  |  |  |
| **FIB-4** | Mansoor *et al*[140], 2015 | United States | Presence of F2-F4 | NAFLD (*n* = 92) | Biopsy |  | 0.686 (0.576-0.797) |  |  |  |  |  |
| **FIB-4** | Mansoor *et al*[140], 2015 | United States | Presence of F3-F4 | NAFLD (*n* = 92) | Biopsy |  | 0.367 (0.231-0.503) |  |  |  |  |  |
| **HA** | Gawrieh *et al*[150], 2021 | United States | Any fibrosis (≥ F1) | NAFLD (*n* = 173), borderline/suspicious NASH (*n* = 73), definite NASH (*n* = 71) | Biopsy |  | 0.57 (0.47–0.67) |  |  |  |  | 0.32 |
| **HA** | Gawrieh *et al*[150], 2021 | United States | Significant fibrosis (≥ F2) | NAFLD (*n* = 173), borderline/suspicious NASH (*n* = 73), definite NASH (*n* = 71) | Biopsy |  | 0.64 (0.54–0.74) |  |  |  |  | 0.002 |
| **HA** | Gawrieh *et al*[150], 2021 | United States | Advanced fibrosis (≥ F3) | NAFLD (*n* = 173), borderline/suspicious NASH (*n* = 73), definite NASH (*n* = 71) | Biopsy |  | 0.77 (0.66–0.88) |  |  |  |  | 0.001 |
| **Hepa-met** | Mosca *et al*[142], 2022 | Italy | ≥ F2 | NAFLD (*n* = 286), F0 (*n* = 105), F1 (*n* = 140), F2 (*n* = 31), F3 (*n* = 2) | Biopsy |  | 0.73 |  |  | 88.8 | 76.6 |  |
| **Hepa-met** | Mosca *et al*[142], 2022 | Italy | > F1 | NAFLD (*n* = 286), F0 (*n* = 105), F1 (*n* = 140), F2 (*n* = 31), F3 (*n* = 2) | Biopsy |  | 0.778 |  |  | 63.2 | 61.3 |  |
| **NFS** | Mansoor *et al*[140], 2015 | United States | Presence of F1-F4 | NAFLD (*n* = 92) | Biopsy |  | 0.470 (0.259-0.681) |  |  |  |  |  |
| **NFS** | Mansoor *et al*[140], 2015 | United States | Presence of F2-F4 | NAFLD (*n* = 92) | Biopsy |  | 0.554 (0.435-0.673) |  |  |  |  |  |
| **NFS** | Mansoor *et al*[140], 2015 | United States | Presence of F3-F4 | NAFLD (*n* = 92) | Biopsy |  | 0.521 (0.385-0.657) |  |  |  |  |  |
| **NFS** | Mosca *et al*[142], 2022 | Italy | > F1 | NAFLD (*n* = 286), F0 (*n* = 105), F1 (*n* = 140), F2 (*n* = 31), F3 (*n* = 2) | Biopsy |  | 0.537 |  |  | 62 | 52 |  |
| **NFS** | Mosca *et al*[142], 2022 | Italy | > F2 | NAFLD (*n* = 286), F0 (*n* = 105), F1 (*n* = 140), F2 (*n* = 31), F3 (*n* = 2) | Biopsy |  | 0.6 |  |  |  |  |  |
| **PIIINP** | Gawrieh *et al*[150], 2021 | United States | Any fibrosis (≥ F1) | NAFLD (*n* = 173), borderline/suspicious NASH (*n* = 73), definite NASH (*n* = 71) | Biopsy |  | 0.55 (0.45–0.65) |  |  |  |  | 0.18 |
| **PIIINP** | Gawrieh *et al*[150], 2021 | United States States | Clinically significant (≥ F2) | NAFLD (*n* = 173), borderline/suspicious NASH (*n* = 73), definite NASH (*n* = 71) | Biopsy |  | 0.66 (0.57–0.75) |  |  |  |  | 0.002 |
| **PIIINP** | Gawrieh *et al*[150], 2021 | United States | Advanced fibrosis (≥ F3) | NAFLD (*n* = 173), borderline/suspicious NASH (*n* = 73), definite NASH (*n* = 71) | Biopsy |  | 0.65 (0.53–0.76) |  |  |  |  | 0.06 |
| **PNFI** | Mosca *et al*[142], 2022 | Italy | > F1 | NAFLD (*n* = 286), F0 (*n* = 105), F1 (*n* = 140), F2 (*n* = 31), F3 (*n* = 2) | Biopsy |  | 0.81 |  |  | 90.3 | 75.4 |  |
| **PNFI** | Nobili *et al*[148], 2009 | Italy | ≥ F1 | NAFLD (*n* = 203), Fibrosis (*n* = 141), no fibrosis (*n* = 62), stage 1 fibrosis (*n* = 115), stage 2 fibrosis (*n* = 9), stage 3 fibrosis (*n* = 17) | Biopsy | ≥ 9 | 0.85 (0.80-0.90) |  |  | 98.5 |  |  |
| **PNFI** | Mosca *et al*[142], 2022 | Italy | > F2 | NAFLD (*n* = 286), F0 (n = 105), F1 (*n* = 140), F2 (n = 31), F3 (*n* = 2) | Biopsy |  | 0.84 |  |  | 97.5 | 72.6 |  |
| **TIMP-1** | Gawrieh *et al*[150], 2021 | United States | Any fibrosis (≥ F1) | NAFLD (*n* = 173), borderline/suspicious NASH (*n* = 73), definite NASH (*n* = 71) | Biopsy |  | 0.63 (0.54–0.72) |  |  |  |  | 0.02 |
| **TIMP-1** | Gawrieh *et al*[150], 2021 | United States | Clinically significant (≥ F2) | NAFLD (*n* = 173), borderline/suspicious NASH (*n* = 73), definite NASH (*n* = 71) | Biopsy |  | 0.63 (0.53–0.72) |  |  |  |  | 0.01 |
| **TIMP-1** | Gawrieh *et al*[150], 2021 | United States | Advanced fibrosis (≥ F3) | NAFLD (*n* = 173), borderline/suspicious NASH (*n* = 73), definite NASH (*n* = 71) | Biopsy |  | 0.76 (0.64–0.88) |  |  |  |  | < 0.001 |

ALT: Alanine aminotransferase; AUROC: Area under the receiver operating characteristic curve; AST: Aspartate aminotransferase; APRI: AST to platelet ratio index; CI: Confidence interval; Dx: Diagnosis; ELF: Enhanced liver fibrosis; F: Fibrosis stage; FAST: FibroScan-aspartate aminotransferase; FIB-4: Fibrosis-4, Fibrosis-4; HA: Hyaluronic acid; NAS: NAFLD activity score; NAFLD: Nonalcoholic fatty liver disease; NFS: NAFLD Fibrosis Score; NPV: Negative predictive value; PIIINP: Amino-terminal propeptide of type III procollagen; PNFI: Pediatric NAFLD Fibrosis Index; PPV: Positive predictive value; Sens: Sensitivity; Spec: Specificity; TIMP-1: Tissue inhibitor of metalloproteinase-1; WC, waist circumference.